

TEKLA LIFE SCIENCES INVESTORS
Form N-PX
August 29, 2016

**UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION**

OMB APPROVAL

OMB Number: 3235-0582
Expires: March 31, 2018
Estimated average burden hours
per response.....7.2

Washington, D.C. 20549

FORM N-PX

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number **811- 06565**

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA
(Address of principal executive offices)

02110
(Zip code)

Laura Woodward
Tekla Life Sciences Investors
100 Federal Street, 19th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Date of reporting period: **7/1/15-6/30/16**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Item 1. Proxy Voting Record.

*Vote Summary***ABAXIS, INC.**

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 002567105 | Meeting Type | Annual |
| Ticker Symbol | ABAX | Meeting Date | 28-Oct-2015 |
| Record Date | 31-Aug-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 CLINTON H. SEVERSON | | For | For |
| | 2 VERNON E. ALTMAN | | For | For |
| | 3 RICHARD J BASTIANI, PHD | | Withheld | Against |
| | 4 MICHAEL D. CASEY | | Withheld | Against |
| | 5 HENK J. EVENHUIS | | For | For |
| | 6 PRITHIPAL SINGH, PH.D. | | For | For |
| 2. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT. | Management | For | For |
| 3. | TO RATIFY THE SELECTION OF BURR PILGER MAYER, INC. AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ABAXIS, INC. FOR THE FISCAL YEAR ENDING MARCH 31, 2016. | Management | For | For |

ACADIA PHARMACEUTICALS INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 004225108 | Meeting Type | Annual |
| Ticker Symbol | ACAD | Meeting Date | 10-Jun-2016 |
| Record Date | 22-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 LAURA BREGE | | For | For |
| | 2 STEPHEN DAVIS | | For | For |
| 2. | TO APPROVE AN AMENDMENT TO OUR 2004 EMPLOYEE STOCK PURCHASE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 400,000 SHARES. | Management | For | For |
| 3. | TO APPROVE AN AMENDMENT TO OUR 2010 EQUITY INCENTIVE PLAN, AS AMENDED, TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 3,000,000 SHARES. | Management | For | For |
| 4. | TO APPROVE, ON AN ADVISORY BASIS, OUR EXECUTIVE COMPENSATION. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|---|------------|-----|-----|
| 5. | TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
|----|---|------------|-----|-----|

ACCELERATE DIAGNOSTICS

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00430H102 | Meeting Type | Annual |
| Ticker Symbol | AXDX | Meeting Date | 06-May-2016 |
| Record Date | 17-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 LAWRENCE MEHREN | | For | For |
| | 2 MARK MILLER | | For | For |
| | 3 JOHN PATIENCE | | For | For |
| | 4 JACK SCHULER | | For | For |
| | 5 MATTHEW STROBECK, PH.D. | | For | For |
| | 6 FRANK J.M. TEN BRINK | | For | For |
| 2. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS | Management | For | For |
| 3. | TO APPROVE THE ACCELERATE DIAGNOSTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN | Management | For | For |
| 4. | TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT PUBLIC ACCOUNTANTS OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016 | Management | For | For |

ADAPTIMMUNE THERAPEUTICS PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00653A107 | Meeting Type | Annual |
| Ticker Symbol | ADAP | Meeting Date | 17-Dec-2015 |
| Record Date | 13-Nov-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| O1 | TO RECEIVE, CONSIDER AND ADOPT THE DIRECTORS AND AUDITOR S REPORTS AND STATEMENT OF ACCOUNTS FOR THE YEAR ENDED 30 JUNE 2015 AND NOTE THAT THE DIRECTORS DO NOT RECOMMEND PAYMENT OF A DIVIDEND. | Management | For | For |
| O2 | TO APPROVE THE DIRECTORS REMUNERATION REPORT. | Management | For | For |
| O3 | TO APPROVE THE DIRECTORS REMUNERATION POLICY WITH EFFECT FROM AFTER THE END OF THE ANNUAL GENERAL MEETING OF THE COMPANY ON 17 DECEMBER 2015. | Management | For | For |
| O4 | TO RE-APPOINT KPMG LLP AS AUDITOR. | Management | For | For |
| O5 | TO AUTHORISE THE DIRECTORS TO DETERMINE THE AUDITOR S REMUNERATION. | Management | For | For |
| O6 | TO AUTHORISE THE DIRECTORS UNDER S551 OF THE COMPANIES ACT 2006 (THE 2006 ACT) TO ALLOT SHARES OR TO GRANT RIGHTS TO SUBSCRIBE FOR OR TO CONVERT ANY SECURITY INTO SHARES. | Management | For | For |
| S7 | TO AUTHORISE THE DIRECTORS TO ALLOT EQUITY SECURITIES UNDER SECTION 570 OF THE 2006 ACT AS IF SECTION 561(1) OF THE 2006 ACT DID NOT APPLY TO SUCH ALLOTMENT. | Management | For | For |

ADAPTIMMUNE THERAPEUTICS PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 00653A107 | Meeting Type | Annual |
| Ticker Symbol | ADAP | Meeting Date | 16-Jun-2016 |
| Record Date | 03-May-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| O1. | TO RECEIVE, CONSIDER AND ADOPT THE DIRECTORS AND AUDITOR S REPORTS AND STATEMENT OF ACCOUNTS FOR THE PERIOD ENDED 31 DECEMBER 2015 AND NOTE THAT THE DIRECTORS DO NOT RECOMMEND PAYMENT OF A DIVIDEND. | Management | For | |
| O2. | TO APPROVE THE DIRECTORS REMUNERATION REPORT. | Management | For | |
| O3. | | Management | For | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|-----|---|------------|-----|
| | TO RE-ELECT JAMES NOBLE AS A DIRECTOR OF THE COMPANY. | | |
| O4. | TO RE-ELECT ELLIOTT SIGAL AS A DIRECTOR OF THE COMPANY. | Management | For |
| O5. | TO RE-APPOINT KPMG LLP AS AUDITOR OF THE COMPANY. | Management | For |
| O6. | TO AUTHORISE THE AUDIT COMMITTEE TO DETERMINE THE AUDITOR S REMUNERATION. | Management | For |
| S7. | TO APPROVE THE AMENDMENT OF THE ARTICLES OF ASSOCIATION OF THE COMPANY. | Management | For |

AKORN, INC.

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | 009728106 AKRX 11-May-2016 | Meeting Type Meeting Date | Annual 01-Jul-2016 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 JOHN KAPOOR, PHD | | For | For |
| | 2 KENNETH ABRAMOWITZ | | For | For |
| | 3 ADRIENNE GRAVES, PHD | | For | For |
| | 4 RONALD JOHNSON | | For | For |
| | 5 STEVEN MEYER | | For | For |
| | 6 TERRY ALLISON RAPPUHN | | For | For |
| | 7 BRIAN TAMBI | | For | For |
| | 8 ALAN WEINSTEIN | | For | For |
| 2. | PROPOSAL TO RATIFY THE APPOINTMENT OF BDO USA, LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | PROPOSAL TO APPROVE, THROUGH A NON-BINDING ADVISORY VOTE, THE COMPANY S EXECUTIVE COMPENSATION PROGRAM AS DESCRIBED IN THE COMPANY S 2016 PROXY STATEMENT. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

ALEXION PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 015351109 | Meeting Type | Annual |
| Ticker Symbol | ALXN | Meeting Date | 11-May-2016 |
| Record Date | 15-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|---------|------------------------|
| 1A. | ELECTION OF DIRECTOR: LEONARD BELL | Management | For | For |
| 1B. | ELECTION OF DIRECTOR: FELIX BAKER | Management | For | For |
| 1C. | ELECTION OF DIRECTOR: DAVID R. BRENNAN | Management | For | For |
| 1D. | ELECTION OF DIRECTOR: M. MICHELE BURNS | Management | For | For |
| 1E. | ELECTION OF DIRECTOR: CHRISTOPHER J. COUGHLIN | Management | For | For |
| 1F. | ELECTION OF DIRECTOR: DAVID L. HALLAL | Management | For | For |
| 1G. | ELECTION OF DIRECTOR: JOHN T. MOLLEN | Management | For | For |
| 1H. | ELECTION OF DIRECTOR: R. DOUGLAS NORBY | Management | For | For |
| 1I. | ELECTION OF DIRECTOR: ALVIN S. PARVEN | Management | For | For |
| 1J. | ELECTION OF DIRECTOR: ANDREAS RUMMELT | Management | For | For |
| 1K. | ELECTION OF DIRECTOR: ANN M. VENEMAN | Management | For | For |
| 2. | APPROVAL OF A NON-BINDING ADVISORY VOTE OF THE 2015 COMPENSATION PAID TO ALEXION S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 3. | RATIFICATION OF APPOINTMENT BY BOARD OF PRICEWATERHOUSECOOPERS LLP AS ALEXION S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. | Management | For | For |
| 4. | TO REQUEST THE BOARD TO AMEND ALEXION S GOVERNING DOCUMENTS TO GIVE SHAREHOLDERS OWNING 10% OF ALEXION STOCK THE POWER TO CALL A SPECIAL MEETING. | Shareholder | Against | For |

ALKERMES PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G01767105 | Meeting Type | Annual |
| Ticker Symbol | ALKS | Meeting Date | 25-May-2016 |
| Record Date | 17-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1.1 | ELECTION OF DIRECTOR: DAVID W. ANSTICE | Management | For | For |
| 1.2 | ELECTION OF DIRECTOR: ROBERT A. BREYER | Management | For | For |
| 1.3 | ELECTION OF DIRECTOR: WENDY L. DIXON, PH.D. | Management | For | For |
| 2. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 3. | TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE INDEPENDENT AUDITOR OF THE COMPANY AND TO AUTHORIZE THE AUDIT AND RISK | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|-----|---|------------|-----|-----|
| | COMMITTEE TO SET THE INDEPENDENT AUDITOR S REMUNERATION ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL). | | | |
| 4. | TO APPROVE THE ALKERMES PLC 2011 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED. | Management | For | For |
| 5. | TO GRANT THE BOARD THE AUTHORITY TO ISSUE SHARES UNDER IRISH LAW. | Management | For | For |
| 6A. | TO APPROVE CERTAIN AMENDMENTS TO THE COMPANY S ARTICLES OF ASSOCIATION THAT ADDRESS THE ADOPTION OF THE IRISH COMPANIES ACT 2014. | Management | For | For |
| 6B. | TO APPROVE CERTAIN AMENDMENTS TO THE COMPANY S MEMORANDUM OF ASSOCIATION THAT ADDRESS THE ADOPTION OF THE IRISH COMPANIES ACT 2014. | Management | For | For |
| 7. | TO GRANT THE BOARD THE AUTHORITY TO OPT-OUT OF STATUTORY PRE-EMPTION RIGHTS UNDER IRISH LAW. | Management | For | For |

ALLERGAN PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G0177J108 | Meeting Type | Annual |
| Ticker Symbol | AGN | Meeting Date | 05-May-2016 |
| Record Date | 07-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 NESLI BASGOZ, M.D. | | For | For |
| | 2 PAUL M. BISARO | | For | For |
| | 3 JAMES H. BLOEM | | For | For |
| | 4 CHRISTOPHER W. BODINE | | For | For |
| | 5 CHRISTOPHER J. COUGHLIN | | For | For |
| | 6 MICHAEL R. GALLAGHER | | For | For |
| | 7 CATHERINE M. KLEMA | | For | For |
| | 8 PETER J. MCDONNELL, M.D | | For | For |
| | 9 PATRICK J. O SULLIVAN | | For | For |
| | 10 BRENTON L. SAUNDERS | | For | For |
| | 11 RONALD R. TAYLOR | | For | For |
| | 12 FRED G. WEISS | | For | For |
| 2. | TO APPROVE, IN A NON-BINDING VOTE, NAMED EXECUTIVE OFFICER COMPENSATION | Management | For | For |
| 3. | TO RATIFY, IN A NON-BINDING VOTE, THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT AUDITOR FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016 AND TO AUTHORIZE, IN A BINDING VOTE, THE BOARD OF DIRECTORS, ACTING THROUGH THE AUDIT AND COMPLIANCE COMMITTEE, TO DETERMINE PRICEWATERHOUSECOOPERS LLP S REMUNERATION | Management | For | For |
| 4A. | TO APPROVE THE AMENDMENT OF THE COMPANY S: MEMORANDUM OF ASSOCIATION TO MAKE CERTAIN ADMINISTRATIVE AMENDMENTS | Management | For | For |
| 4B. | TO APPROVE THE AMENDMENT OF THE COMPANY S: ARTICLES OF ASSOCIATION TO MAKE CERTAIN ADMINISTRATIVE AMENDMENTS | Management | For | For |
| 5A. | TO APPROVE THE AMENDMENT OF THE COMPANY S ARTICLES OF ASSOCIATION IN ORDER TO: PROVIDE FOR A PLURALITY VOTING STANDARD IN THE EVENT OF A CONTESTED ELECTION | Management | For | For |
| 5B. | TO APPROVE THE AMENDMENT OF THE COMPANY S ARTICLES OF ASSOCIATION IN ORDER TO: GRANT THE BOARD OF DIRECTORS SOLE AUTHORITY TO DETERMINE ITS SIZE | Management | For | For |
| 6. | TO APPROVE THE REDUCTION OF COMPANY CAPITAL | Management | For | For |
| 7. | TO CONSIDER A SHAREHOLDER PROPOSAL REGARDING AN ANNUAL REPORT ON LOBBYING ACTIVITIES, IF PROPERLY PRESENTED AT THE MEETING | Shareholder | Against | For |
| 8. | TO CONSIDER A SHAREHOLDER PROPOSAL REGARDING AN INDEPENDENT BOARD CHAIRMAN, IF PROPERLY PRESENTED AT THE MEETING | Shareholder | Against | For |

ALLIQUA BIOMEDICAL, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 019621200 | Meeting Type | Annual |
| Ticker Symbol | ALQA | Meeting Date | 06-May-2016 |
| Record Date | 11-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 DAVID JOHNSON | | For | For |
| | 2 WINSTON KUNG | | For | For |
| | 3 JOSEPH LEONE | | For | For |
| | 4 GARY RESTANI | | For | For |
| | 5 JEFFREY SKLAR | | For | For |
| | 6 MARK WAGNER | | For | For |
| | 7 JEROME ZELDIS, MD, PHD. | | For | For |
| 2. | APPROVAL OF AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 45,714,286 TO 95,000,000. | Management | For | For |
| 3. | RATIFICATION OF THE APPOINTMENT OF MARCUM LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

ALNYLAM PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 02043Q107 | Meeting Type | Annual |
| Ticker Symbol | ALNY | Meeting Date | 03-May-2016 |
| Record Date | 11-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | ELECTION OF CLASS III DIRECTOR: STEVEN M. PAUL, M.D. | Management | For | For |
| 1.2 | ELECTION OF CLASS III DIRECTOR: AMY W. SCHULMAN | Management | For | For |
| 1.3 | ELECTION OF CLASS III DIRECTOR: KEVIN P. STARR | Management | For | For |
| 2. | TO APPROVE, IN A NON-BINDING ADVISORY VOTE, THE COMPENSATION OF ALNYLAM S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 3. | TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AS ALNYLAM S INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

ALTERG, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 1-Feb-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | WAIVER OF REQUIREMENT FOR AUDITED FINANCIAL STATEMENTS | Management | For | For |
| 2 | ADDITIONAL PROVISIONS | Management | For | For |

AMGEN INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 031162100 | Meeting Type | Annual |
| Ticker Symbol | AMGN | Meeting Date | 19-May-2016 |
| Record Date | 21-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1A. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. DAVID BALTIMORE | Management | For | For |
| 1B. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. FRANK J. BIONDI, JR. | Management | For | For |
| 1C. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. ROBERT A. BRADWAY | Management | For | For |
| 1D. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. FRANCOIS DE CARBONNEL | Management | For | For |
| 1E. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. ROBERT A. ECKERT | Management | For | For |
| 1F. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. GREG C. GARLAND | Management | For | For |
| 1G. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. FRED HASSAN | Management | For | For |
| 1H. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. REBECCA M. HENDERSON | Management | For | For |
| 1I. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. FRANK C. HERRINGER | Management | For | For |
| 1J. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. TYLER JACKS | Management | For | For |
| 1K. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MS. JUDITH C. PELHAM | Management | For | For |
| 1L. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. RONALD D. SUGAR | Management | For | For |
| 1M. | ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. R. SANDERS WILLIAMS | Management | For | For |
| 2. | TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|---|-------------|---------|-----|
| 3. | ADVISORY VOTE TO APPROVE OUR EXECUTIVE COMPENSATION. | Management | For | For |
| 4. | STOCKHOLDER PROPOSAL TO CHANGE THE VOTING STANDARD APPLICABLE TO NON-BINDING PROPOSALS SUBMITTED BY STOCKHOLDERS. | Shareholder | Against | For |

AMICUS THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 03152W109 | Meeting Type | Annual |
| Ticker Symbol | FOLD | Meeting Date | 09-Jun-2016 |
| Record Date | 15-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 JOHN F. CROWLEY | | For | For |
| | 2 MARGARET G. MCGLYNN RPH | | For | For |
| | 3 MICHAEL G. RAAB | | For | For |
| | 4 GLENN P. SBLENDORIO | | For | For |
| 2. | APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN. | Management | For | For |
| 3. | APPROVE THE ISSUANCE OF SHARES OF THE COMPANY S COMMON STOCK IN CONNECTION WITH A SPECIFIC MILESTONE PAYMENT THAT MAY BECOME PAYABLE TO THE FORMER SCIODERM STOCKHOLDERS, IN ACCORDANCE WITH THE MARKETPLACE RULES OF THE NASDAQ STOCK MARKET, LLC. | Management | For | For |
| 4. | RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 5. | APPROVE, ON AN ADVISORY BASIS, THE COMPANY S EXECUTIVE COMPENSATION. | Management | For | For |

ANACOR PHARMACEUTICALS INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 032420101 | Meeting Type | Annual |
| Ticker Symbol | ANAC | Meeting Date | 07-Jun-2016 |
| Record Date | 12-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 PAUL L. BERNS | | For | For |
| | 2 LUCY SHAPIRO, PH.D. | | For | For |
| | 3 WENDELL WIERENGA, PH.D. | | For | For |
| 2. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 4. | TO RE-APPROVE THE SECTION 162(M) PERFORMANCE GOALS UNDER THE COMPANY'S 2010 EQUITY INCENTIVE PLAN. | Management | For | For |

ARDELYX, INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 039697107 | Meeting Type | Annual |
| Ticker Symbol | ARDX | Meeting Date | 02-Jun-2016 |
| Record Date | 08-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 DAVID MOTT | | For | For |
| | 2 MICHAEL RAAB | | For | For |
| 2. | TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD OF DIRECTORS, OF ERNST & YOUNG, LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016. | Management | For | For |

ARIAD PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 04033A100 | Meeting Type | Annual |
| Ticker Symbol | ARIA | Meeting Date | 21-Jul-2016 |
| Record Date | 25-May-2016 | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | TO ADOPT AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO DECLASSIFY THE BOARD OF DIRECTORS AND PROVIDE FOR THE ANNUAL ELECTION OF DIRECTORS. | Management | For | For |
| 2A. | TO ELECT CLASS 1 DIRECTOR TO SERVE ON OUR BOARD OF DIRECTORS: ALEXANDER J. DENNER, PH.D. | Management | For | For |
| 3. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT. | Management | For | For |
| 4. | TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2016. | Management | For | For |

AURIS MEDICAL HOLDING AG

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | H03579101 | Meeting Type | Annual |
| Ticker Symbol | EARS | Meeting Date | 08-Apr-2016 |
| Record Date | 10-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| G1 | GENERAL INSTRUCTIONS ON THE PROPOSALS OF THE BOARD OF DIRECTORS | Management | For | For |
| G2 | GENERAL INSTRUCTIONS ON NEW PROPOSALS OF THE BOARD OF DIRECTORS/ NEW AGENDA ITEMS | Management | For | For |
| S1 | APPROVAL OF THE ANNUAL REPORT, THE FINANCIAL STATEMENTS AND THE GROUP CONSOLIDATED FINANCIAL STATEMENTS FOR THE 2015 FINANCIAL YEAR | Management | For | For |
| S2 | DISCHARGE OF THE MEMBERS OF THE BOARD AND THE PERSONS ENTRUSTED WITH THE COMPANY S MANAGEMENT | Management | For | For |
| S3 | APPROPRIATION OF FINANCIAL RESULTS | Management | For | For |
| S4A | INCREASE AND AMENDMENT OF THE AUTHORIZED SHARE CAPITAL | Management | For | For |
| S4B | INCREASE AND AMENDMENT OF THE CONDITIONAL SHARE CAPITAL | Management | For | For |
| S4C | CANCELLATION OF ARTICLE 5 OF THE ARTICLES OF ASSOCIATION | Management | For | For |
| S5A | APPROVAL OF THE COMPENSATION OF THE BOARD OF DIRECTORS | Management | For | For |
| S5B | APPROVAL OF THE COMPENSATION OF THE MEMBERS OF THE EXECUTIVE MANAGEMENT COMMITTEE FOR THE 2015 FINANCIAL YEAR | Management | For | For |
| S5C | APPROVAL OF THE COMPENSATION OF THE MEMBERS OF THE EXECUTIVE MANAGEMENT COMMITTEE FOR THE 2017 FINANCIAL YEAR | Management | For | For |
| S6A | RE-ELECTION OF THOMAS MEYER AS MEMBER AND CHAIRMAN | Management | For | For |
| S6B | RE-ELECTION OF JAMES I. HEALY AS MEMBER OF THE BOARD | Management | For | For |
| S6C | RE-ELECTION OF WOLFGANG ARNOLD AS MEMBER OF THE BOARD | Management | For | For |
| S6D | RE-ELECTION OF OLIVER KUBLI AS MEMBER OF THE BOARD | Management | For | For |
| S6E | RE-ELECTION OF BERNDT A. MODIG AS MEMBER OF THE BOARD | Management | For | For |
| S6F | RE-ELECTION OF ANTOINE PAPIERNIK AS MEMBER OF THE BOARD | Management | For | For |
| S6G | RE-ELECTION OF CALVIN W. ROBERTS AS MEMBER OF THE BOARD | Management | For | For |
| S6H | ELECTION OF ARMANDO ANIDO AS MEMBER OF THE BOARD | Management | For | For |
| S7A | RE-ELECTION OF JAMES I. HEALY AS MEMBER OF THE COMPENSATION COMMITTEE | Management | For | For |
| S7B | RE-ELECTION OF ANTOINE PAPIERNIK AS MEMBER OF THE COMPENSATION COMMITTEE | Management | For | For |
| S7C | | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

ELECTION OF ARMANDO ANIDO AS MEMBER OF
THE COMPENSATION COMMITTEE

| | | | | |
|----|--|------------|-----|-----|
| S8 | RE-ELECTION OF DELOITTE AG AS AUDITORS | Management | For | For |
| S9 | RE-ELECTION OF THE INDEPENDENT PROXY SANDRO G. TOBLER | Management | For | For |

BELLICUM PHARMACEUTICALS INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 079481107 | Meeting Type | Annual |
| Ticker Symbol | BLCM | Meeting Date | 15-Jun-2016 |
| Record Date | 18-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 JAMES F. BROWN | | For | For |
| | 2 KEVIN M. SLAWIN, M.D. | | For | For |
| 2. | RATIFICATION OF SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

BIODELIVERY SCIENCES INTERNATIONAL, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 09060J106 | Meeting Type | Annual |
| Ticker Symbol | BDSI | Meeting Date | 16-Jul-2015 |
| Record Date | 05-Jun-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 FRANCIS E. O DONNELL JR | | For | For |
| | 2 SAMUEL P. SEARS, JR. | | For | For |
| | 3 BARRY I. FEINBERG | | For | For |
| 2. | TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE COMPANY S BOARD OF DIRECTORS OF CHERRY BEKAERT LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2015. | Management | For | For |
| 3. | TO APPROVE AN AMENDMENT TO THE 2011 EQUITY INCENTIVE PLAN TO, AMONG OTHER MATTERS, INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2011 PLAN FROM 8,800,000 TO 11,050,000. | Management | For | For |
| 4. | IN THEIR DISCRETION, UPON THE TRANSACTION OF ANY OTHER MATTERS WHICH MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

BIOGEN INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 09062X103 | Meeting Type | Annual |
| Ticker Symbol | BIIB | Meeting Date | 08-Jun-2016 |
| Record Date | 11-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1A. | ELECTION OF DIRECTOR: ALEXANDER J. DENNER | Management | For | For |
| 1B. | ELECTION OF DIRECTOR: CAROLINE D. DORSA | Management | For | For |
| 1C. | ELECTION OF DIRECTOR: NANCY L. LEAMING | Management | For | For |
| 1D. | ELECTION OF DIRECTOR: RICHARD C. MULLIGAN | Management | For | For |
| 1E. | ELECTION OF DIRECTOR: ROBERT W. PANGIA | Management | For | For |
| 1F. | ELECTION OF DIRECTOR: STELIOS PAPADOPOULOS | Management | For | For |
| 1G. | ELECTION OF DIRECTOR: BRIAN S. POSNER | Management | For | For |
| 1H. | ELECTION OF DIRECTOR: ERIC K. ROWINSKY | Management | For | For |
| 1I. | ELECTION OF DIRECTOR: GEORGE A. SCANGOS | Management | For | For |
| 1J. | ELECTION OF DIRECTOR: LYNN SCHENK | Management | For | For |
| 1K. | ELECTION OF DIRECTOR: STEPHEN A. SHERWIN | Management | For | For |
| 2. | TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS BIOGEN INC. S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | SAY ON PAY - TO APPROVE AN ADVISORY VOTE ON EXECUTIVE COMPENSATION. | Management | For | For |

BIOMARIN PHARMACEUTICAL INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 09061G101 | Meeting Type | Annual |
| Ticker Symbol | BMRN | Meeting Date | 06-Jun-2016 |
| Record Date | 11-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 JEAN-JACQUES BIENAIME | | For | For |
| | 2 MICHAEL GREY | | For | For |
| | 3 ELAINE J. HERON | | For | For |
| | 4 V. BRYAN LAWLIS | | For | For |
| | 5 ALAN J. LEWIS | | For | For |
| | 6 RICHARD A. MEIER | | For | For |
| | 7 DAVID PYOTT | | For | For |
| | 8 DENNIS J. SLAMON | | For | For |
| 2. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF BIOMARIN S NAMED EXECUTIVE OFFICERS AS DEFINED AND DISCLOSED IN ITS PROXY STATEMENT. | Management | For | For |
| 3. | | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

TO RATIFY THE SELECTION OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR BIOMARIN FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.

| | | | | |
|----|---|-------------|---------|-----|
| 4. | A STOCKHOLDER PROPOSAL REQUESTING THAT BIOMARIN ISSUE A SUSTAINABILITY REPORT DESCRIBING BIOMARIN'S ENVIRONMENTAL, SOCIAL AND GOVERNANCE PERFORMANCE, IF PROPERLY PRESENTED AT BIOMARIN'S ANNUAL MEETING OF STOCKHOLDERS. | Shareholder | Against | For |
|----|---|-------------|---------|-----|

BLUEBIRD BIO INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 09609G100 | Meeting Type | Annual |
| Ticker Symbol | BLUE | Meeting Date | 02-Jun-2016 |
| Record Date | 08-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 WENDY DIXON | | For | For |
| | 2 JAMES MANDELL | | For | For |
| | 3 DAVID SCHENKEIN | | For | For |
| 2. | ADVISORY VOTE ON EXECUTIVE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 3. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

CARDIOKINETIX, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 11-Apr-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | ELECTION OF DANIEL OMSTEAD TO THE BOARD OF DIRECTORS | Management | For | For |
| 2 | OMNIBUS RESOLUTIONS | Management | For | For |

CELATOR PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 15089R102 | Meeting Type | Annual |
| Ticker Symbol | CPXX | Meeting Date | 06-Jun-2016 |
| Record Date | 22-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 MICHAEL R. DOUGHERTY | | For | For |
| | 2 SCOTT T. JACKSON | | For | For |
| | 3 JEAN-PIERRE BIZZARI | | For | For |
| | 4 RICHARD S. KOLLENDER | | For | For |
| | 5 JOSEPH M. LOBACKI | | For | For |
| | 6 JOSEPH A. MOLLIKA | | For | For |
| | 7 SCOTT MORENSTEIN | | For | For |
| | 8 NICOLE VITULLO | | For | For |
| 2. | THE RATIFICATION OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

CELGENE CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 151020104 | Meeting Type | Annual |
| Ticker Symbol | CELG | Meeting Date | 15-Jun-2016 |
| Record Date | 18-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---------------------------|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 ROBERT J. HUGIN | | For | For |
| | 2 MARK J. ALLES | | For | For |
| | 3 RICHARD W BARKER D PHIL | | For | For |
| | 4 MICHAEL W. BONNEY | | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | | |
|----|----|---|-------------|---------|-----|
| | 5 | MICHAEL D. CASEY | | For | For |
| | 6 | CARRIE S. COX | | For | For |
| | 7 | JACQUALYN A. FOUSE, PHD | | For | For |
| | 8 | MICHAEL A. FRIEDMAN, MD | | For | For |
| | 9 | JULIA A. HALLER, M.D. | | For | For |
| | 10 | GILLA S. KAPLAN, PH.D. | | For | For |
| | 11 | JAMES J. LOUGHLIN | | For | For |
| | 12 | ERNEST MARIO, PH.D. | | For | For |
| 2. | | RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | | APPROVAL OF AN AMENDMENT TO THE COMPANY S 2008 STOCK INCENTIVE PLAN. | Management | For | For |
| 4. | | APPROVAL, BY NON-BINDING VOTE, OF EXECUTIVE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 5. | | RATIFICATION OF AN AMENDMENT TO THE COMPANY S BY-LAWS. | Management | For | For |
| 6. | | STOCKHOLDER PROPOSAL TO REQUEST A BY-LAW PROVISION GRANTING STOCKHOLDERS THE RIGHT TO CALL SPECIAL MEETINGS, DESCRIBED IN MORE DETAIL IN THE PROXY STATEMENT. | Shareholder | Against | For |
| 7. | | STOCKHOLDER PROPOSAL TO REQUEST A PROXY ACCESS BY-LAW PROVISION, DESCRIBED IN MORE DETAIL IN THE PROXY STATEMENT. | Shareholder | Against | For |

CELLECTIS S.A.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 15117K103 | Meeting Type | Annual |
| Ticker Symbol | CLLS | Meeting Date | 17-May-2016 |
| Record Date | 18-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | APPROVAL OF THE ANNUAL FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 | Management | For | For |
| 2. | APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 | Management | For | For |
| 3. | ALLOCATION OF INCOME FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 | Management | For | For |
| 4. | APPROVAL OF THE AGREEMENTS REFERRED TO IN ARTICLES L. 225-38 AND FOLLOWING OF THE FRENCH COMMERCIAL CODE | Management | For | For |
| 5. | REAPPOINTMENT OF MR. MATHIEU SIMON TO THE BOARD OF DIRECTORS | Management | For | For |
| 6. | AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS TO BUY BACK COMPANY SHARES | Management | For | For |
| 7. | AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF REDUCING THE SHARE CAPITAL THROUGH THE CANCELLATION OF SHARES IN THE CONTEXT OF THE AUTHORIZATION TO BUY BACK ITS OWN SHARES | Management | For | For |
| 8. | DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|-----|--|------------|-----|-----|
| | INCREASING THE SHARE CAPITAL BY ISSUING ORDINARY SHARES AND/OR ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL AND/OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS, IN FAVOR OF A CATEGORY OF PERSONS MEETING SPECIFIED CHARACTERISTICS | | | |
| 9. | DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL THROUGH THE ISSUANCE OF ORDINARY SHARES OR OF ANY SECURITIES WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS, IN FAVOR OF A CATEGORY OF PERSONS ENSURING THE UNDERWRITING OF THE COMPANY'S EQUITY SECURITIES THAT MAY ARISE AS PART OF A LINE OF EQUITY FINANCING | Management | For | For |
| 10. | DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL IMMEDIATELY OR IN THE FUTURE BY ISSUING ORDINARY SHARES OR ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WHILE MAINTAINING THE PREFERENTIAL SUBSCRIPTION RIGHTS | Management | For | For |
| 11. | DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL IMMEDIATELY OR IN THE FUTURE THROUGH THE ISSUANCE OF ORDINARY SHARES OR OF ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS AND PUBLIC OFFERING | Management | For | For |
| 12. | DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL THROUGH THE ISSUANCE OF ORDINARY SHARES AND/OR OF ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS OF THE SHAREHOLDERS, THROUGH AN OFFER TO QUALIFIED INVESTORS OR A LIMITED CIRCLE OF INVESTORS WITHIN THE MEANING OF PARAGRAPH II OF ARTICLE L. 411-2 OF THE FRENCH MONETARY AND FINANCIAL CODE | Management | For | For |
| 13. | DELEGATION GRANTED TO THE BOARD OF DIRECTORS TO INCREASE THE NUMBER OF SECURITIES TO BE ISSUED IN CASE OF SHARE CAPITAL INCREASE WITH OR WITHOUT PREFERENTIAL SUBSCRIPTION RIGHTS | Management | For | For |
| 14. | OVERALL LIMITATIONS TO THE AMOUNT OF ISSUANCES MADE UNDER THE EIGHTH RESOLUTION, THE NINTH RESOLUTION, THE | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

TENTH RESOLUTION, THE ELEVENTH RESOLUTION, THE TWELFTH RESOLUTION AND THE THIRTEENTH RESOLUTION ABOVE

| | | | | |
|-----|---|-------------|---------|-----|
| 15. | DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL BY INCORPORATION OF PREMIUMS, RESERVES, PROFITS OR OTHERS | Management | For | For |
| 16. | AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS TO GRANT OPTIONS TO SUBSCRIBE OR PURCHASE COMPANY S SHARES | Management | For | For |
| 17. | AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS FOR THE ALLOCATION OF FREE SHARES EXISTING AND/OR TO BE ISSUED IN THE FUTURE | Management | For | For |
| 18. | DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS TO ISSUE AND GRANT SHARE WARRANTS TO (I) MEMBERS AND NON-VOTING MEMBERS (CENSEURS) OF THE COMPANY S BOARD OF DIRECTORS IN OFFICE ON THE DATE THE WARRANTS ARE GRANTED WHO ARE NOT EMPLOYEES OR SENIOR EXECUTIVES OF THE COMPANY OR ONE OF ITS SUBSIDIARIES OR (II) PERSONS WHO HAVE ENTERED INTO A SERVICES OR CONSULTANTS CONTRACT WITH THE COMPANY OR WITH ONE OF ITS SUBSIDIARIES OR (III) MEMBERS OF ANY COMMITTEE WHICH THE BOARD OF DIRECTORS ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL) | Management | For | For |
| 19. | DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF ISSUING WARRANTS TO SUBSCRIBE TO AND/OR ACQUIRE REDEEMABLE SHARES (BSAAR) OR SHARE SUBSCRIPTION WARRANTS - WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS IN FAVOR OF THE FOLLOWING CATEGORY OF BENEFICIARIES: EMPLOYEES AND CORPORATE OFFICERS OF THE COMPANY AND ITS SUBSIDIARIES | Management | For | For |
| 20. | AUTHORIZATION FOR THE BOARD OF DIRECTORS TO FREELY ALLOCATE PREFERRED SHARES OF THE COMPANY TO THE EMPLOYEES AND/OR THE EXECUTIVE OFFICERS OF THE COMPANY AND ITS SUBSIDIARIES ENTAILING THE WAIVER BY THE SHAREHOLDERS OF THEIR PREFERENTIAL SUBSCRIPTION RIGHTS | Management | For | For |
| 21. | OVERALL LIMITATIONS TO THE AMOUNT OF ISSUES MADE UNDER THE SIXTEENTH RESOLUTION, THE SEVENTEENTH RESOLUTION, THE EIGHTEENTH RESOLUTION, THE NINETEENTH RESOLUTION AND THE TWENTIETH RESOLUTION ABOVE | Management | For | For |
| 22. | DELEGATION TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF AN INCREASE IN THE SHARE CAPITAL WHOSE SUBSCRIPTION WOULD BE RESERVED TO MEMBERS OF A COMPANY SAVINGS PLAN ESTABLISHED PURSUANT TO ARTICLES L. 3332-18 AND FOLLOWING OF THE FRENCH LABOR CODE | Shareholder | Against | For |

CEPHEID

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 15670R107 | Meeting Type | Annual |
| Ticker Symbol | CPHD | Meeting Date | 26-Apr-2016 |
| Record Date | 04-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1A. | TO ELECT CLASS II DIRECTOR TO SERVE FOR A THREE-YEAR TERM: THOMAS L. GUTSHALL | Management | For | For |
| 1B. | TO ELECT CLASS II DIRECTOR TO SERVE FOR A THREE-YEAR TERM: CRISTINA H. KEPNER | Management | For | For |
| 1C. | TO ELECT CLASS II DIRECTOR TO SERVE FOR A THREE-YEAR TERM: DAVID H. PERSING, M.D., PH.D. | Management | For | For |
| 2. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF CEPHEID FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | TO APPROVE A NON-BINDING ADVISORY RESOLUTION ON CEPHEID S EXECUTIVE COMPENSATION. | Management | For | For |

CHIMERIX INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 16934W106 | Meeting Type | Annual |
| Ticker Symbol | CMRX | Meeting Date | 24-Jun-2016 |
| Record Date | 27-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|---------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 C L GILLISS PHD RN FAAN | | For | For |
| | 2 C. PATRICK MACHADO | | For | For |
| | 3 ERNEST MARIO, PH.D. | | For | For |
| 2. | RATIFICATION OF THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | TO APPROVE, BY NON-BINDING VOTE, THE COMPENSATION OF CHIMERIX, INC. S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT. | Management | Against | Against |
| 4. | TO RECOMMEND, BY NON-BINDING VOTE, THE FREQUENCY OF EXECUTIVE COMPENSATION VOTES. | Management | 1 Year | For |

CIDARA THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 171757107 | Meeting Type | Annual |
| Ticker Symbol | CDTX | Meeting Date | 22-Jun-2016 |
| Record Date | 25-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 SCOTT ROCKLAGE, PH.D. | | For | For |
| | 2 JEFFREY STEIN, PH.D. | | For | For |
| 2. | RATIFICATION OF THE APPOINTMENT OF THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016 | Management | For | For |

CYTOMX THERAPEUTICS, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 01-Oct-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | APPROVAL OF REVERSE STOCK SPLIT; AUTHORIZATION OF AMENDMENT AND RESTATEMENT OF CERTIFICATE OF INCORPORATION | Management | For | For |
| 2 | WRITTEN CONSENT: COUNTERPARTS | Management | For | For |

CYTOMX THERAPEUTICS, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 06-Oct-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | APPROVAL OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION | Management | For | For |
| 2 | ADOPTION OF AMENDED AND RESTATED BYLAWS | Management | For | For |
| 3 | FURTHER GRANT OF AUTHORITY | Management | For | For |

CYTOMX THERAPEUTICS, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 23284F105 | Meeting Type | Annual |
| Ticker Symbol | CTMX | Meeting Date | 10-Jun-2016 |
| Record Date | 12-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1A. | ELECTION OF DIRECTOR: SEAN A. MCCARTHY | Management | For | For |
| 2. | TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | TO ADOPT AND APPROVE THE CYTOMX THERAPEUTICS, INC. ANNUAL INCENTIVE PLAN. | Management | For | For |
| 4. | TO APPROVE THE PERFORMANCE MEASURES INCLUDED IN THE CYTOMX THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN. | Management | For | For |

DEPOMED, INC.

| | | | |
|----------------------|-------------|---------------------|-------------------|
| Security | 249908104 | Meeting Type | Contested-Consent |
| Ticker Symbol | DEPO | Meeting Date | 20-Nov-2015 |
| Record Date | 29-Oct-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 01 | THIS PROPOSAL REFERS TO THE WHITE CARD. THIS VIF, WHEN PROPERLY EXECUTED, WILL GRANT HORIZON A PROXY TO REQUEST THE REMOVAL AND BYLAW AMENDMENTS SPECIAL MEETING BUT WILL NOT GRANT HORIZON AUTHORITY TO VOTE ON ANY MATTER PRESENTED AT THE REMOVAL AND BYLAW AMENDMENTS SPECIAL MEETING. A PROPERLY EXECUTED VIF FOR WHICH NO INSTRUCTION IS GIVEN WILL GRANT HORIZON A PROXY TO REQUEST THE REMOVAL AND BYLAW AMENDMENTS SPECIAL MEETING. | Management | Against | Against |
| 02 | THIS PROPOSAL REFERS TO THE BLUE CARD. THIS VIF, WHEN PROPERLY EXECUTED, WILL GRANT HORIZON A PROXY TO REQUEST THE ELECTION SPECIAL MEETING BUT WILL NOT GRANT HORIZON AUTHORITY TO VOTE ON ANY MATTER PRESENTED AT THE ELECTION SPECIAL MEETING. A PROPERLY EXECUTED VIF FOR WHICH NO INSTRUCTION IS GIVEN WILL GRANT HORIZON A PROXY TO REQUEST THE ELECTION SPECIAL MEETING. | Management | Against | Against |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

DEPOMED, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 249908104 | Meeting Type | Annual |
| Ticker Symbol | DEPO | Meeting Date | 18-May-2016 |
| Record Date | 31-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | ELECTION OF DIRECTOR: PETER D. STAPLE | Management | For | For |
| 1.2 | ELECTION OF DIRECTOR: KAREN A. DAWES | Management | For | For |
| 1.3 | ELECTION OF DIRECTOR: LOUIS J. LAVIGNE, JR. | Management | For | For |
| 1.4 | ELECTION OF DIRECTOR: SAMUEL R. SAKS, M.D. | Management | For | For |
| 1.5 | ELECTION OF DIRECTOR: JAMES A. SCHOENECK | Management | For | For |
| 1.6 | ELECTION OF DIRECTOR: DAVID B. ZENOFF, D.B.A. | Management | For | For |
| 2. | TO APPROVE AN INCREASE IN THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE COMPANY S AMENDED AND RESTATED 2014 OMNIBUS INCENTIVE PLAN. | Management | For | For |
| 3. | TO APPROVE AN INCREASE IN THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE COMPANY S AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN. | Management | For | For |
| 4. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 5. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

DYNAVAX TECHNOLOGIES CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 268158201 | Meeting Type | Annual |
| Ticker Symbol | DVAX | Meeting Date | 31-May-2016 |
| Record Date | 06-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 DENNIS A. CARSON, M.D. | | For | For |
| | 2 EDDIE GRAY | | For | For |
| | 3 LAURA BREGE | | For | For |
| 2. | TO AMEND AND RESTATE THE DYNAVAX TECHNOLOGIES CORPORATION 2011 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THAT PLAN BY 3,200,000, AND TO APPROVE THE AWARD LIMITS AND OTHER TERMS APPLICABLE TO AWARDS INTENDED TO QUALIFY AS PERFORMANCE-BASED COMPENSATION | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

FOR PURPOSES OF SECTION 162(M) OF THE INTERNAL REVENUE CODE.

| | | | | |
|----|--|------------|-----|-----|
| 3. | TO AMEND AND RESTATE THE DYNAVAX TECHNOLOGIES CORPORATION 2014 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THAT PLAN BY 200,000. | Management | For | For |
| 4. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT. | Management | For | For |
| 5. | TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

ENDO INTERNATIONAL PLC

| | | | |
|---|----------------------------------|----------------------------------|-----------------------|
| Security Ticker Symbol Record Date | G30401106 ENDP 14-Apr-2016 | Meeting Type Meeting Date | Annual 09-Jun-2016 |
|---|----------------------------------|----------------------------------|-----------------------|

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1A. | ELECTION OF DIRECTOR: ROGER H. KIMMEL | Management | For | For |
| 1B. | ELECTION OF DIRECTOR: RAJIV DE SILVA | Management | For | For |
| 1C. | ELECTION OF DIRECTOR: SHANE M. COOKE | Management | For | For |
| 1D. | ELECTION OF DIRECTOR: ARTHUR J. HIGGINS | Management | For | For |
| 1E. | ELECTION OF DIRECTOR: NANCY J. HUTSON, PH.D. | Management | For | For |
| 1F. | ELECTION OF DIRECTOR: MICHAEL HYATT | Management | For | For |
| 1G. | ELECTION OF DIRECTOR: WILLIAM P. MONTAGUE | Management | For | For |
| 1H. | ELECTION OF DIRECTOR: JILL D. SMITH | Management | For | For |
| 1I. | ELECTION OF DIRECTOR: WILLIAM F. SPENGLER | Management | For | For |
| 2. | TO APPROVE THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY'S INDEPENDENT AUDITORS FOR THE YEAR ENDING DECEMBER 31, 2016 AND TO AUTHORIZE THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS TO DETERMINE THE AUDITORS' REMUNERATION. | Management | For | For |
| 3. | TO APPROVE, BY ADVISORY VOTE, NAMED EXECUTIVE OFFICER COMPENSATION. | Management | For | For |
| 4. | TO APPROVE THE AMENDMENT OF THE COMPANY'S MEMORANDUM OF ASSOCIATION. | Management | For | For |
| 5. | TO APPROVE THE AMENDMENT OF THE COMPANY'S ARTICLES OF ASSOCIATION. | Management | For | For |
| 6. | TO APPROVE THE AMENDMENT OF THE COMPANY'S 2015 STOCK INCENTIVE PLAN. | Management | For | For |
| 1J. | ELECTION OF DIRECTOR: DOUGLAS S. INGRAM | Management | For | For |
| 1K. | ELECTION OF DIRECTOR: TODD SISITSKY | Management | For | For |

EPIZYME INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 29428V104 | Meeting Type | Annual |
| Ticker Symbol | EPZM | Meeting Date | 19-May-2016 |
| Record Date | 01-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 DAVID M. MOTT | | For | For |
| | 2 RICHARD F. POFS | | For | For |
| 2. | RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS EPIZYME S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

EXELIXIS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 30161Q104 | Meeting Type | Annual |
| Ticker Symbol | EXEL | Meeting Date | 25-May-2016 |
| Record Date | 31-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1.1 | ELECTION OF CLASS II DIRECTOR: CARL B. FELDBAUM, ESQ. | Management | For | For |
| 1.2 | ELECTION OF CLASS II DIRECTOR: ALAN M. GARBER, M.D., PH.D. | Management | For | For |
| 1.3 | ELECTION OF CLASS II DIRECTOR: VINCENT T. MARCHESI, M.D., PH.D. | Management | For | For |
| 2. | TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS EXELIXIS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 30, 2016. | Management | For | For |
| 3. | TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE EXELIXIS, INC. 2000 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE UNDER THE 2000 EMPLOYEE STOCK PURCHASE PLAN BY 5,000,000 SHARES AND MAKE CERTAIN OTHER CHANGES AS DESCRIBED IN PROPOSAL 3 OF THE ACCOMPANYING PROXY STATEMENT. | Management | For | For |
| 4. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF EXELIXIS NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE ACCOMPANYING PROXY STATEMENT. | Management | For | For |

FLEX PHARMA INC

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 33938A105 | Meeting Type | Annual |
| Ticker Symbol | FLKS | Meeting Date | 07-Jun-2016 |
| Record Date | 11-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 MARC KOZIN | | For | For |
| | 2 RODERICK MACKINNON | | For | For |
| | 3 MICHELLE STACY | | For | For |
| 2. | TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

FOAMIX PHARMACEUTICALS LTD

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | M46135105 | Meeting Type | Annual |
| Ticker Symbol | FOMX | Meeting Date | 18-Apr-2016 |
| Record Date | 15-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1. | APPOINT KESSELMAN & KESSELMAN, A MEMBER FIRM OF PRICEWATERHOUSECOOPERS INTERNATIONAL LIMITED, AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016, AND AUTHORIZE THE BOARD TO DETERMINE THE COMPENSATION OF THE AUDITORS. | Management | For | For |
| 2. | APPROVE THE FOLLOWING RESOLUTIONS WITH REGARD TO THE COMPENSATION OF DR. DOV TAMARKIN, OUR CHIEF EXECUTIVE OFFICER: (A) GRANT DR. TAMARKIN A CASH BONUS OF \$181,837 FOR THE YEAR ENDED DECEMBER 31, 2015, BASED ON THE ACHIEVEMENT OF THE GOALS SET AND EVALUATED BY OUR COMPENSATION COMMITTEE; (B) INCREASE DR. TAMARKIN'S ANNUAL BASE SALARY TO \$385,000, EFFECTIVE NOVEMBER 1, 2015; AND (C) AWARD DR. TAMARKIN 100,000 OPTIONS UNDER THE COMPANY'S 2015 ISRAELI SHARE INCENTIVE PLAN. | Management | For | For |
| 2B. | IF YOU DO NOT HAVE A PERSONAL INTEREST MARK FOR= YES. IF YOU DO NOT MARK FOR=YES, YOUR VOTE FOR PROP 2 WILL NOT BE VALID | Management | For | |
| 3. | APPROVE DR. TAMARKIN'S (A) ANNUAL CASH BONUS FOR THE YEAR ENDING DECEMBER 31, 2016, UP TO A MAXIMUM AMOUNT OF \$231,000, SUBJECT TO ACHIEVING THE KEY PERFORMANCE INDICATORS DETAILED IN THE PROXY STATEMENT, AND (B) AN ADDITIONAL SPECIAL CASH BONUS, FOR THE YEAR ENDING DECEMBER 31, 2016, IN AN AMOUNT OF UP TO \$231,000, UPON UNIQUE SUCCESS BEYOND EXPECTATIONS IN ACHIEVING CERTAIN GOALS DETAILED IN THE PROXY STATEMENT, IN EACH CASE, SUBJECT TO THE RECOMMENDATIONS OF THE COMPANY'S COMPENSATION COMMITTEE AND THE BOARD APPROVAL. | Management | Against | Against |
| 3B. | IF YOU DO NOT HAVE A PERSONAL INTEREST MARK FOR= YES. IF YOU DO NOT MARK FOR=YES, YOUR VOTE FOR PROP 3 WILL NOT BE VALID | Management | For | |
| 4. | APPROVE THE FOLLOWING RESOLUTIONS WITH REGARD TO THE COMPENSATION OF MEIR EINI, CHAIRMAN OF THE BOARD AND CHIEF INNOVATION OFFICER: (A) GRANT MR. EINI A | Management | Against | Against |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

CASH BONUS OF \$200,777 FOR THE YEAR ENDED DECEMBER 31, 2015, BASED ON THE ACHIEVEMENT OF THE GOALS SET AND EVALUATED BY OUR COMPENSATION COMMITTEE; (B) INCREASE MR. EINI S ANNUAL BASE SALARY TO \$369,000, EFFECTIVE NOVEMBER 1, 2015; AND (C) AWARD MR. EINI 55,000 OPTIONS UNDER THE COMPANY S 2015 ISRAELI SHARE INCENTIVE PLAN.

| | | | | |
|----|--|------------|---------|---------|
| 5. | APPROVE MR. EINI S (A) ANNUAL CASH BONUS FOR THE YEAR ENDING DECEMBER 31, 2016, UP TO A MAXIMUM AMOUNT OF \$184,500, SUBJECT TO ACHIEVING THE KEY PERFORMANCE INDICATORS DETAILED IN THIS PROXY STATEMENT, AND (B) AN ADDITIONAL SPECIAL CASH BONUS, FOR THE YEAR ENDING DECEMBER 31, 2016, IN AN AMOUNT OF UP TO \$184,500, UPON UNIQUE SUCCESS BEYOND EXPECTATIONS IN ACHIEVING CERTAIN GOALS DETAILED IN THIS PROXY STATEMENT, IN EACH CASE, SUBJECT TO THE RECOMMENDATIONS OF THE COMPANY S COMPENSATION COMMITTEE AND THE BOARD APPROVAL. | Management | Against | Against |
|----|--|------------|---------|---------|

GALAPAGOS N V

| | | | |
|----------------------|------------|---------------------|-------------|
| Security | 36315X101 | Meeting Type | Special |
| Ticker Symbol | GLPG | Meeting Date | 22-Dec-2015 |
| Record Date | 8-Dec-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | TO CONFIRM THE APPOINTMENT OF DR. CHRISTINE MUMMERY AS DIRECTOR OF THE COMPANY. | Management | For | For |
| 2. | TO APPROVE THE PROPOSAL TO OFFER ADDITIONAL WARRANTS. | Management | For | For |

GALAPAGOS N V

| | | | |
|----------------------|------------|---------------------|-------------|
| Security | 36315X101 | Meeting Type | Annual |
| Ticker Symbol | GLPG | Meeting Date | 26-Apr-2016 |
| Record Date | 7-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 2. | COMMUNICATION AND APPROVAL OF THE NON-CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015 AND THE ALLOCATION OF THE ANNUAL RESULT AS PROPOSED BY THE BOARD OF DIRECTORS. | Management | For | For |
| 5. | COMMUNICATION AND APPROVAL OF THE REMUNERATION REPORT. | Management | For | For |
| 6. | RELEASE FROM LIABILITY TO BE GRANTED TO THE DIRECTORS AND THE STATUTORY AUDITOR FOR THE PERFORMANCE OF THEIR DUTIES IN THE COURSE OF THE FINANCIAL YEAR ENDED 31 DECEMBER 2015. | Management | For | For |
| 7. | REMUNERATION OF DIRECTORS. | Management | For | For |
| 8. | OFFER OF WARRANTS. | Management | For | For |
| 9. | APPLICATION OF ARTICLE 556 OF THE BELGIAN COMPANIES CODE. | Management | For | For |
| E2. | AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL BY UP TO 20% OF THE SHARE CAPITAL. | Management | For | For |
| E3. | AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL BY UP TO 50% OF THE SHARE CAPITAL, IN SPECIFIC CIRCUMSTANCES. | Management | For | For |
| E4. | AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL BY UP TO 100% OF THE SHARE CAPITAL, IN SPECIFIC CIRCUMSTANCES WITH UNANIMOUS CONSENT. | Management | For | For |
| E5. | AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL AFTER NOTIFICATION OF A PUBLIC TAKEOVER BID. | Management | For | For |

GALAPAGOS NV, MECHELEN

| | | | |
|----------------------|------------|---------------------|-------------------------|
| Security | B44170106 | Meeting Type | Special General Meeting |
| Ticker Symbol | GLPG | Meeting Date | 22-Dec-2015 |
| Record Date | 8-Dec-2015 | | |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| CMMT | IMPORTANT MARKET PROCESSING REQUIREMENT: A BENEFICIAL OWNER SIGNED POWER OF ATTORNEY (POA) MAY BE REQUIRED IN ORDER TO LODGE AND EXECUTE YOUR VOTING INSTRUCTIONS IN THIS MARKET. ABSENCE OF A POA, MAY CAUSE YOUR INSTRUCTIONS TO BE REJECTED. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT YOUR CLIENT SERVICE REPRESENTATIVE | Non-Voting | | |
| CMMT | MARKET RULES REQUIRE DISCLOSURE OF BENEFICIAL OWNER INFORMATION FOR ALL VOTED ACCOUNTS. IF AN ACCOUNT HAS MULTIPLE BENEFICIAL OWNERS, YOU WILL NEED TO PROVIDE THE BREAKDOWN OF EACH BENEFICIAL OWNER NAME, ADDRESS AND SHARE-POSITION TO YOUR CLIENT SERVICE REPRESENTATIVE. THIS INFORMATION IS REQUIRED IN ORDER FOR YOUR VOTE TO BE LODGED | Non-Voting | | |
| 1 | CONFIRMATION OF APPOINTMENT OF INDEPENDENT DIRECTOR: THE SHAREHOLDERS MEETING RESOLVES TO CONFIRM THE APPOINTMENT OF DR. CHRISTINE MUMMERY (RESIDING IN BILTHOVEN, THE NETHERLANDS) AS A DIRECTOR OF THE COMPANY, MADE BY THE BOARD AS FROM 30 SEPTEMBER 2015 TO FILL A VACANCY, AND TO APPOINT HER AS A DIRECTOR OF THE COMPANY FOR A PERIOD OF FOUR YEARS ENDING IMMEDIATELY AFTER THE SHAREHOLDERS MEETING IN 2019 WHICH HAS THE APPROVAL OF THE ANNUAL ACCOUNTS ON ITS AGENDA. UPON THE PROPOSAL OF THE BOARD AND IN ACCORDANCE WITH THE ADVICE OF THE COMPANY S NOMINATION AND REMUNERATION COMMITTEE, THE SHAREHOLDERS MEETING FURTHER RESOLVES TO APPOINT DR. MUMMERY AS AN INDEPENDENT DIRECTOR AS SHE MEETS THE CRITERIA OF INDEPENDENCE SET FORTH IN ARTICLE 526TER OF THE BELGIAN COMPANIES CODE AND DR. MUMMERY EXPRESSLY STATED, AND AS FAR AS THE BOARD IS AWARE, SHE DOES NOT HAVE ANY RELATIONSHIP WITH ANY COMPANY THAT WOULD COMPROMISE HER INDEPENDENCE. THE SHAREHOLDERS MEETING ACKNOWLEDGES THAT THE BOARD MAY DETERMINE THE REMUNERATION TO BE GRANTED TO DR. MUMMERY FOR THE EXERCISE OF HER MANDATE AS A DIRECTOR OF THE COMPANY WITHIN THE LIMITS OF THE POWER OF ATTORNEY UNANIMOUSLY APPROVED BY THE SHAREHOLDERS MEETING ON 28 APRIL 2015 (EIGHTH AGENDA ITEM - REMUNERATION OF DIRECTORS) | Management | For | For |
| 2 | OFFER OF WARRANTS: THE SHAREHOLDERS MEETING RESOLVES TO APPROVE THE PROPOSAL OF THE COMPANY S NOMINATION AND REMUNERATION COMMITTEE TO OFFER ADDITIONAL WARRANTS TO THE COMPANY S DIRECTORS IN LIGHT OF AN INDEPENDENT | Management | For | For |

BENCHMARKING EXERCISE AND RECOMMENDATION BY AN EXTERNAL ADVISOR, FOLLOWING THE GROWTH OF THE COMPANY AND THE RECENT US LISTING OF THE COMPANY ON NASDAQ AND CONSEQUENTLY (I) RESOLVES TO OFFER 100,000 WARRANTS TO MR. ONNO VAN DE STOLPE, 15,000 WARRANTS TO DR. RAJ PAREKH, AND 7,500 WARRANTS TO EACH OF DR. WERNER CAUTREELS, DR. HARROLD VAN BARLINGEN, MR. HOWARD ROWE, MS. KATRINE BOSLEY AND DR. CHRISTINE MUMMERY, UNDER WARRANT PLANS TO BE CREATED BY THE BOARD OF DIRECTORS FOR THE BENEFIT OF DIRECTORS, EMPLOYEES AND INDEPENDENT CONSULTANTS OF GALAPAGOS AND ITS AFFILIATES WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL (JOINTLY WARRANT PLAN 2015 (B)), THE KEY CONDITIONS OF WHICH WILL BE IN LINE WITH PREVIOUS WARRANT PLANS OF THE COMPANY, (II) EMPOWERS THE MANAGING DIRECTOR, AS WELL AS ANY OTHER DIRECTOR AS REGARDS THE OFFER TO THE MANAGING DIRECTOR, TO IMPLEMENT THIS OFFER, AND (III) TO THE EXTENT REQUIRED, APPROVES THE OFFER OF WARRANTS TO MEMBERS OF GALAPAGOS EXECUTIVE COMMITTEE UNDER WARRANT PLAN 2015 ... (DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)

GALAPAGOS NV, MECHELEN

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | B44170106 | Meeting Type | MIX |
| Ticker Symbol | GLPG | Meeting Date | 26-Apr-2016 |
| Record Date | 12-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| CMMT | MARKET RULES REQUIRE DISCLOSURE OF BENEFICIAL OWNER INFORMATION FOR ALL VOTED ACCOUNTS. IF AN ACCOUNT HAS MULTIPLE BENEFICIAL OWNERS, YOU WILL NEED TO-PROVIDE THE BREAKDOWN OF EACH BENEFICIAL OWNER NAME, ADDRESS AND SHARE-POSITION TO YOUR CLIENT SERVICE REPRESENTATIVE. THIS INFORMATION IS REQUIRED IN ORDER FOR YOUR VOTE TO BE LODGED | Non-Voting | | |
| CMMT | IMPORTANT MARKET PROCESSING REQUIREMENT: A BENEFICIAL OWNER SIGNED POWER OF ATTORNEY (POA) MAY BE REQUIRED IN ORDER TO LODGE AND EXECUTE YOUR VOTING INSTRUCTIONS IN THIS MARKET. ABSENCE OF A POA, MAY CAUSE YOUR INSTRUCTIONS TO BE REJECTED. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT YOUR CLIENT SERVICE REPRESENTATIVE | Non-Voting | | |
| A.1 | COMMUNICATION AND DISCUSSION OF THE ANNUAL REPORT OF THE BOARD OF DIRECTORS RELATING TO THE NON-CONSOLIDATED AND CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015, AND OF THE REPORT OF THE STATUTORY AUDITOR RELATING TO THE NON-CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015 | Non-Voting | | |
| A.2 | THE SHAREHOLDERS MEETING RESOLVES TO APPROVE THE NON-CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015, AS WELL AS THE ALLOCATION OF THE ANNUAL RESULT AS PROPOSED BY THE BOARD OF DIRECTORS | Management | For | For |
| A.3 | COMMUNICATION AND DISCUSSION OF THE REPORT OF THE STATUTORY AUDITOR RELATING TO THE CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR-ENDED ON 31 DECEMBER 2015 | Non-Voting | | |
| A.4 | COMMUNICATION AND DISCUSSION OF THE CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015 | Non-Voting | | |
| A.5 | THE SHAREHOLDERS MEETING RESOLVES TO APPROVE THE REMUNERATION REPORT | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|-----|---|------------|-----|-----|
| A.6 | THE SHAREHOLDERS MEETING RESOLVES, BY SEPARATE VOTE, TO RELEASE EACH DIRECTOR AND THE STATUTORY AUDITOR FROM ANY LIABILITY ARISING FROM THE PERFORMANCE OF THEIR DUTIES DURING THE LAST FINANCIAL YEAR | Management | For | For |
| A.7 | UPON RECOMMENDATION OF THE COMPANY S NOMINATION AND REMUNERATION COMMITTEE, THE SHAREHOLDERS MEETING RESOLVES THAT (A) THE COMPENSATION (EXCLUDING EXPENSES) OF THE NON-EXECUTIVE DIRECTORS FOR THE EXERCISE OF THEIR MANDATE DURING THE FINANCIAL YEAR ENDING 31 DECEMBER 2016 IS ESTABLISHED AS FOLLOWS: (I) CHAIRMAN OF THE BOARD: EUR 80,000; (II) OTHER NON-EXECUTIVE BOARD MEMBERS: EUR 40,000 EACH; (III) ANNUAL ADDITIONAL COMPENSATION FOR MEMBERSHIP OF A BOARD COMMITTEE: EUR 5,000; (IV) ANNUAL ADDITIONAL COMPENSATION FOR THE CHAIRMANSHIP OF A BOARD COMMITTEE: EUR 10,000; AND (B) POWER OF ATTORNEY IS GRANTED TO THE BOARD OF DIRECTORS TO DETERMINE THE TOTAL REMUNERATION PACKAGE OF THE MANAGING DIRECTOR (CEO) FOR HIS MANAGEMENT FUNCTION IN THE COMPANY, IT BEING UNDERSTOOD THAT THIS REMUNERATION SHALL INCLUDE A COMPENSATION FOR THE PERFORMANCE OF HIS MANDATE AS A DIRECTOR OF THE COMPANY | Management | For | For |
| A.8 | UPON RECOMMENDATION OF THE COMPANY S NOMINATION AND REMUNERATION COMMITTEE, THE SHAREHOLDERS MEETING (I) RESOLVES TO OFFER 100,000 WARRANTS TO MR. ONNO VAN DE STOLPE, 15,000 WARRANTS TO DR. RAJ PAREKH, AND 7,500 WARRANTS TO EACH OF DR. WERNER CAUTREELS, DR. HARROLD VAN BARLINGEN, MR. HOWARD ROWE, MS. KATRINE BOSLEY AND DR. CHRISTINE MUMMERY, UNDER WARRANT PLANS TO BE CREATED BY THE BOARD OF DIRECTORS FOR THE BENEFIT OF DIRECTORS, EMPLOYEES AND INDEPENDENT CONSULTANTS OF GALAPAGOS AND ITS AFFILIATES WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL (JOINTLY WARRANT PLAN 2016), THE KEY CONDITIONS OF WHICH WILL BE IN LINE WITH PREVIOUS WARRANT PLANS OF THE COMPANY, (II) EMPOWERS THE MANAGING DIRECTOR, AS WELL AS ANY OTHER DIRECTOR AS REGARDS THE OFFER TO THE MANAGING DIRECTOR, TO IMPLEMENT THIS OFFER, AND (III) TO THE EXTENT REQUIRED, APPROVES THE OFFER OF WARRANTS TO MEMBERS OF GALAPAGOS EXECUTIVE COMMITTEE UNDER WARRANT PLAN 2016 IN ACCORDANCE WITH GALAPAGOS REMUNERATION POLICY AND PRACTICES... (DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL) | Management | For | For |
| A.9 | IN ACCORDANCE WITH ARTICLE 556 OF THE BELGIAN COMPANIES CODE, THE SHAREHOLDERS MEETING RESOLVES TO APPROVE, AND TO THE EXTENT REQUIRED, | Management | For | For |

RATIFY ALL OF THE PROVISIONS GRANTING RIGHTS TO THIRD PARTIES WHICH COULD AFFECT THE ASSETS OF THE COMPANY, OR COULD IMPOSE AN OBLIGATION ON THE COMPANY, WHERE THE EXERCISE OF THOSE RIGHTS IS DEPENDENT ON A PUBLIC TAKEOVER BID ON THE SHARES OF THE COMPANY OR A CHANGE OF CONTROL IN RESPECT OF THE COMPANY, AS INCLUDED IN: (A) THE LICENSE AND COLLABORATION AGREEMENT BETWEEN GALAPAGOS NV AND GILEAD BIOPHARMACEUTICS IRELAND UNLIMITED COMPANY DATED 16 DECEMBER 2015 (THE LICENSE AND COLLABORATION AGREEMENT) INCLUDING, BUT NOT LIMITED TO, CLAUSE 15.6 (ASSIGNMENT; INDUSTRY TRANSACTION; ACQUIRED PROGRAMS) OF THE LICENSE AND COLLABORATION AGREEMENT, ENTITLING THE COUNTERPARTY (I) IN THE EVENT OF AN INDUSTRY TRANSACTION INVOLVING THE COMPANY, AS A RESULT OF WHICH A DRUG COMPANY OF A CERTAIN MINIMUM SIZE ACQUIRES CONTROL OVER THE COMPANY, TO TERMINATE THE COMPANY S CO-PROMOTION RIGHTS, TO DISBAND ALL JOINT COMMITTEES AND UNDERTAKE EXCLUSIVE CONTROL OF THEIR ACTIVITIES; AND (II) IN THE EVENT OF A CHANGE OF CONTROL AS A RESULT OF WHICH THE COMPANY ACQUIRES RIGHTS TO AN ALTERNATIVE PRODUCT THAT WOULD VIOLATE CERTAIN OF COMPANY S EXCLUSIVITY OBLIGATIONS UNDER THE LICENSE AND COLLABORATION AGREEMENT...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).

| | | | | |
|------|---|------------|-----|-----|
| A.10 | MISCELLANEOUS | Non-Voting | | |
| E.1 | CONSIDERATION AND DISCUSSION OF THE SPECIAL REPORT OF THE BOARD OF DIRECTORS- IN ACCORDANCE WITH ARTICLE 604 OF THE BELGIAN COMPANIES CODE RELATING TO THE RENEWAL OF ITS AUTHORIZATION WITH RESPECT TO, AND THE INCREASE OF, THE AUTHORIZED CAPITAL | Non-Voting | | |
| E.2 | THE SHAREHOLDERS MEETING RESOLVES TO DELETE SECTIONS (1) THROUGH (3) OF THE TEMPORARY PROVISIONS OF THE ARTICLES OF ASSOCIATION OF THE COMPANY ENTIRELY AND TO REPLACE THEM WITH THE FOLLOWING TEXT: AUTHORIZED CAPITAL THE BOARD OF DIRECTORS HAS BEEN GRANTED THE AUTHORITY TO INCREASE THE SHARE CAPITAL OF THE COMPANY, IN ACCORDANCE WITH ARTICLES 603 TO 608 OF THE COMPANIES CODE, IN ONE OR SEVERAL TIMES, TO THE EXTENT SET FORTH HEREAFTER. THIS AUTHORIZATION IS VALID FOR A PERIOD OF FIVE YEARS FROM THE DATE OF PUBLICATION OF THIS AUTHORIZATION IN THE ANNEXES TO THE BELGIAN STATE GAZETTE. WITHOUT PREJUDICE TO MORE RESTRICTIVE RULES SET FORTH BY LAW, THE BOARD OF DIRECTORS CAN INCREASE THE SHARE CAPITAL OF THE COMPANY IN ONE | Management | For | For |

OR SEVERAL TIMES WITH AN AMOUNT OF UP TO EUR [AS SPECIFIED], I.E. 20% OF THE SHARE CAPITAL AT THE TIME OF THE CONVENING OF THE SHAREHOLDERS MEETING GRANTING THIS AUTHORIZATION. IN ACCORDANCE WITH ARTICLE 607 OF THE COMPANIES CODE, THE BOARD OF DIRECTORS CANNOT USE THE AFOREMENTIONED AUTHORIZATION AFTER THE FINANCIAL SERVICES AND MARKETS AUTHORITY (FSMA) HAS NOTIFIED THE COMPANY OF A PUBLIC TAKEOVER BID FOR THE COMPANY S SHARES THE CAPITAL INCREASES WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL MAY BE ACHIEVED BY THE ISSUANCE OF SHARES (WITH OR WITHOUT VOTING RIGHTS...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)

| | | | | |
|-----|--|------------|-----|-----|
| E.3 | <p>SHAREHOLDERS MEETING RESOLVES TO ADD A NEW SECTION TO THE TEMPORARY PROVISIONS OF THE ARTICLES OF ASSOCIATION OF THE COMPANY, AS FOLLOWS: USE OF AUTHORIZED CAPITAL IN SPECIFIC CIRCUMSTANCES THE BOARD OF DIRECTORS HAS BEEN GRANTED THE AUTHORITY TO INCREASE THE SHARE CAPITAL OF THE COMPANY, IN ACCORDANCE WITH ARTICLES 603 TO 608 OF THE COMPANIES CODE, IN ONE OR SEVERAL TIMES, TO THE EXTENT SET FORTH HEREAFTER. THIS AUTHORIZATION IS VALID FOR A PERIOD OF FIVE YEARS FROM THE DATE OF PUBLICATION OF THIS AUTHORIZATION IN THE ANNEXES TO THE BELGIAN STATE GAZETTE. WITHOUT PREJUDICE TO MORE RESTRICTIVE RULES SET FORTH BY LAW, BUT ALSO WITHOUT PREJUDICE TO ANY OTHER LESS RESTRICTIVE AUTHORIZATIONS GRANTED BY THE EXTRAORDINARY SHAREHOLDERS MEETING OF [DATE OF THIS MEETING] 2016, THE BOARD OF DIRECTORS CAN INCREASE THE SHARE CAPITAL OF THE COMPANY IN ONE OR SEVERAL TIMES WITH AN AMOUNT UP TO EUR [AS SPECIFIED], I.E. 50% OF THE SHARE CAPITAL AT THE TIME OF THE CONVENING OF THE SHAREHOLDERS MEETING GRANTING THIS AUTHORIZATION, UPON A RESOLUTION OF THE BOARD OF DIRECTORS THAT ALL INDEPENDENT DIRECTORS (WITHIN THE MEANING OF ARTICLE 526TER OF THE COMPANIES CODE) APPROVED AND RELATING TO ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).</p> | Management | For | For |
|-----|--|------------|-----|-----|

| | | | | |
|-----|--|------------|-----|-----|
| E.4 | <p>THE SHAREHOLDERS MEETING RESOLVES TO ADD A NEW SECTION TO THE TEMPORARY PROVISIONS OF THE ARTICLES OF ASSOCIATION OF THE COMPANY, AS FOLLOWS: USE OF AUTHORIZED CAPITAL IN SPECIFIC CIRCUMSTANCES WITH UNANIMOUS CONSENT THE BOARD OF DIRECTORS HAS BEEN GRANTED THE AUTHORITY TO INCREASE THE SHARE CAPITAL OF THE COMPANY, IN ACCORDANCE WITH ARTICLES 603 TO 608 OF THE COMPANIES CODE, IN ONE OR SEVERAL TIMES, TO THE EXTENT SET FORTH HEREAFTER. THIS</p> | Management | For | For |
|-----|--|------------|-----|-----|

AUTHORIZATION IS VALID FOR A PERIOD OF FIVE YEARS FROM THE DATE OF PUBLICATION OF THIS AUTHORIZATION IN THE ANNEXES TO THE BELGIAN STATE GAZETTE. WITHOUT PREJUDICE TO MORE RESTRICTIVE RULES SET FORTH BY LAW, BUT ALSO WITHOUT PREJUDICE TO ANY OTHER LESS RESTRICTIVE AUTHORIZATIONS GRANTED BY THE EXTRAORDINARY SHAREHOLDERS MEETING OF [DATE OF THIS MEETING] 2016, THE BOARD OF DIRECTORS CAN INCREASE THE SHARE CAPITAL OF THE COMPANY IN ONE OR SEVERAL TIMES WITH AN AMOUNT UP TO EUR [AS SPECIFIED], I.E. 100% OF THE SHARE CAPITAL AT THE TIME OF THE CONVENING OF THE SHAREHOLDERS MEETING GRANTING THIS AUTHORIZATION...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)

| | | | | |
|-----|---|------------|-----|-----|
| E.5 | <p>THE SHAREHOLDERS MEETING RESOLVES TO ADD A NEW SECTION TO THE TEMPORARY PROVISIONS OF THE ARTICLES OF ASSOCIATION OF THE COMPANY, AS FOLLOWS: USE OF THE AUTHORIZATION TO INCREASE THE SHARE CAPITAL AFTER NOTIFICATION OF A PUBLIC TAKEOVER BID, UP TO ONE TENTH OF THE SHARES REPRESENTING THE CAPITAL OF THE COMPANY THAT IS ISSUED PRIOR TO SUCH CAPITAL INCREASE THE BOARD OF DIRECTORS IS EXPRESSLY AUTHORIZED DURING A PERIOD OF THREE YEARS AS OF THE DATE OF THE SHAREHOLDERS MEETING WHICH GRANTED THIS AUTHORIZATION, I.E. [DATE OF THIS MEETING] 2016, TO INCREASE THE COMPANY S SHARE CAPITAL WITHIN THE CONTEXT OF THE AUTHORIZED CAPITAL BY CONTRIBUTIONS IN KIND OR IN CASH WITH RESTRICTION OR CANCELLATION OF THE SHAREHOLDERS PREFERENTIAL SUBSCRIPTION RIGHTS, EVEN AFTER THE FINANCIAL SERVICES AND MARKETS AUTHORITY (FSMA) HAS NOTIFIED THE COMPANY OF A PUBLIC TAKEOVER BID FOR THE COMPANY S SHARES, PROVIDED THAT THE RELEVANT PROVISIONS OF THE COMPANIES CODE (INCLUDING BUT NOT LIMITED TO ARTICLE 607 OF THE COMPANIES CODE) ARE COMPLIED WITH, INCLUDING THAT THE NUMBER OF SHARES ISSUED UNDER SUCH CAPITAL INCREASE DOES NOT EXCEED ONE TENTH OF THE SHARES REPRESENTING THE CAPITAL OF THE COMPANY THAT HAVE BEEN ISSUED PRIOR TO SUCH CAPITAL INCREASE. USE OF THE AFOREMENTIONED AUTHORIZATION REQUIRES A UNANIMOUS RESOLUTION OF THE BOARD OF DIRECTORS AT WHICH ALL DIRECTORS ARE PRESENT OR REPRESENTED. THE AUTHORIZATION REFERRED TO ABOVE MAY BE RENEWED</p> | Management | For | For |
|-----|---|------------|-----|-----|

GENMARK DIAGNOSTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 372309104 | Meeting Type | Annual |
| Ticker Symbol | GNMK | Meeting Date | 26-May-2016 |
| Record Date | 30-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 LISA M. GILES | | For | For |
| | 2 MICHAEL S. KAGNOFF | | For | For |
| 2. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS. | Management | For | For |

GILEAD SCIENCES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 375558103 | Meeting Type | Annual |
| Ticker Symbol | GILD | Meeting Date | 11-May-2016 |
| Record Date | 16-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1A. | ELECTION OF DIRECTOR: JOHN F. COGAN, PH.D. | Management | For | For |
| 1B. | ELECTION OF DIRECTOR: KEVIN E. LOFTON | Management | For | For |
| 1C. | ELECTION OF DIRECTOR: JOHN W. MADIGAN | Management | For | For |
| 1D. | ELECTION OF DIRECTOR: JOHN C. MARTIN, PH.D. | Management | For | For |
| 1E. | ELECTION OF DIRECTOR: JOHN F. MILLIGAN, PH.D. | Management | For | For |
| 1F. | ELECTION OF DIRECTOR: NICHOLAS G. MOORE | Management | For | For |
| 1G. | ELECTION OF DIRECTOR: RICHARD J. WHITLEY, M.D. | Management | For | For |
| 1H. | ELECTION OF DIRECTOR: GAYLE E. WILSON | Management | For | For |
| 1I. | ELECTION OF DIRECTOR: PER WOLD-OLSEN | Management | For | For |
| 2. | TO RATIFY THE SELECTION OF ERNST & YOUNG LLP BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF GILEAD FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | TO APPROVE THE AMENDED AND RESTATED GILEAD SCIENCES, INC. CODE SECTION 162(M) BONUS PLAN. | Management | For | For |
| 4. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS PRESENTED IN THE PROXY STATEMENT. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|--|-------------|---------|-----|
| 5. | TO VOTE ON A STOCKHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT THE BOARD TAKE STEPS TO PERMIT STOCKHOLDER ACTION BY WRITTEN CONSENT. | Shareholder | Against | For |
|----|--|-------------|---------|-----|

HALOZYME THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 40637H109 | Meeting Type | Annual |
| Ticker Symbol | HALO | Meeting Date | 04-May-2016 |
| Record Date | 10-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 JEFFREY W. HENDERSON | | For | For |
| | 2 CONNIE L. MATSUI | | For | For |
| | 3 HELEN I. TORLEY | | For | For |
| 2. | TO APPROVE, BY ADVISORY VOTE, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 3. | TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 4. | TO APPROVE AMENDMENTS TO THE COMPANY S 2011 STOCK PLAN. | Management | For | For |
| 5. | TO APPROVE THE COMPANY S EXECUTIVE INCENTIVE PLAN. | Management | For | For |

IDEXX LABORATORIES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 45168D104 | Meeting Type | Annual |
| Ticker Symbol | IDXX | Meeting Date | 04-May-2016 |
| Record Date | 08-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | ELECTION OF DIRECTOR: JONATHAN W. AYERS | Management | For | For |
| 1.2 | ELECTION OF DIRECTOR: BARRY C. JOHNSON, PHD | Management | For | For |
| 1.3 | ELECTION OF DIRECTOR: M. ANNE SZOSTAK | Management | For | For |
| 2. | TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURRENT FISCAL YEAR | Management | For | For |
| 3. | TO APPROVE A NONBINDING ADVISORY RESOLUTION ON THE COMPANY S EXECUTIVE COMPENSATION | Management | For | For |

ILLUMINA, INC.

| | | | |
|-----------------|-----------|---------------------|--------|
| Security | 452327109 | Meeting Type | Annual |
|-----------------|-----------|---------------------|--------|

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Ticker Symbol ILMN **Meeting Date** 18-May-2016
Record Date 21-Mar-2016

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1A. | ELECTION OF DIRECTOR: FRANCES ARNOLD, PH.D. | Management | For | For |
| 1B. | ELECTION OF DIRECTOR: FRANCIS A. DESOUZA | Management | For | For |
| 1C. | ELECTION OF DIRECTOR: KARIN EASTHAM, CPA | Management | For | For |
| 2. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING JANUARY 1, 2017. | Management | For | For |
| 3. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT. | Management | For | For |
| 4. | TO APPROVE, ON AN ADVISORY BASIS, THE RATIFICATION OF CERTAIN SUPERMAJORITY VOTING PROVISIONS IN OUR CERTIFICATE OF INCORPORATION AND BYLAWS. | Management | For | For |

ILLUMINOSS MEDICAL, INC.

Security N/A **Meeting Type** Written Consent
Ticker Symbol N/A **Meeting Date** 05-Nov-2015
Record Date N/A

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|----------------------------|-------------|------|------------------------|
| 1 | CONVERTIBLE NOTE FINANCING | Management | For | For |
| 2 | AMENDED CHARTER | Management | For | For |
| 3 | GENERAL RESOLUTIONS | Management | For | For |

ILLUMINOSS MEDICAL, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 11-Jan-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | APPROVAL OF FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION | Management | For | For |
| 2 | SERIES AA PREFERRED STOCK PURCHASE AND EXCHANGE AGREEMENT | Management | For | For |
| 3 | WAIVER OF RIGHT OF SUBSCRIPTION RIGHTS | Management | For | For |
| 4 | AMENDMENT TO THE CORPORATION S 2007 STOCK OPTIONS/STOCK ISSUANCE PLAN | Management | For | For |
| 5 | BLUESKY AGREEMENT | Management | For | For |
| 6 | ELECTION OF DIRECTORS | Management | For | For |
| 7 | GENERAL RESOLUTIONS | Management | For | For |

IMPAX LABORATORIES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 45256B101 | Meeting Type | Special |
| Ticker Symbol | IPXL | Meeting Date | 08-Dec-2015 |
| Record Date | 26-Oct-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | TO APPROVE AN AMENDMENT TO THE COMPANY S RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF THE COMPANY S COMMON STOCK, PAR VALUE \$0.01 PER SHARE, FROM 90,000,000 SHARES TO 150,000,000 SHARES. | Management | For | For |

IMPAX LABORATORIES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 45256B101 | Meeting Type | Annual |
| Ticker Symbol | IPXL | Meeting Date | 17-May-2016 |
| Record Date | 06-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | ELECTION OF DIRECTOR: LESLIE Z. BENET, PH.D. | Management | For | For |
| 1.2 | ELECTION OF DIRECTOR: ROBERT L. BURR | Management | For | For |
| 1.3 | ELECTION OF DIRECTOR: ALLEN CHAO, PH.D. | Management | For | For |
| 1.4 | ELECTION OF DIRECTOR: MARY K. PENDERGAST, J.D. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|-----|---|------------|-----|-----|
| 1.5 | ELECTION OF DIRECTOR: PETER R. TERRERI | Management | For | For |
| 1.6 | ELECTION OF DIRECTOR: JANET S. VERGIS | Management | For | For |
| 1.7 | ELECTION OF DIRECTOR: G. FREDERICK WILKINSON | Management | For | For |
| 2. | TO APPROVE THE THIRD AMENDMENT AND RESTATEMENT OF OUR 2002 EQUITY INCENTIVE PLAN TO, AMONG OTHER ITEMS, INCREASE THE AGGREGATE NUMBER OF SHARES OF OUR COMMON STOCK THAT MAY BE ISSUED UNDER SUCH PLAN. | Management | For | For |
| 3. | TO APPROVE, BY NON-BINDING VOTE, NAMED EXECUTIVE OFFICER COMPENSATION. | Management | For | For |
| 4. | RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

INCYTE CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 45337C102 | Meeting Type | Annual |
| Ticker Symbol | INCY | Meeting Date | 27-May-2016 |
| Record Date | 08-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 JULIAN C. BAKER | | For | For |
| | 2 JEAN-JACQUES BIENAIME | | For | For |
| | 3 PAUL A. BROOKE | | For | For |
| | 4 PAUL J. CLANCY | | For | For |
| | 5 WENDY L. DIXON | | For | For |
| | 6 PAUL A. FRIEDMAN | | For | For |
| | 7 HERVE HOPPENOT | | For | For |
| 2. | TO APPROVE AMENDMENTS TO THE COMPANY S AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN. | Management | For | For |
| 3. | TO APPROVE AN AMENDMENT TO THE COMPANY S 1997 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE THEREUNDER BY 500,000 SHARES, FROM 8,350,000 SHARES TO 8,850,000 SHARES. | Management | For | For |
| 4. | TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 5. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2016. | Management | For | For |

INOTEK PHARMACEUTICALS CORPORATION

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 45780V102 | Meeting Type | Annual |
| Ticker Symbol | ITEK | Meeting Date | 23-Jun-2016 |
| Record Date | 28-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|------------------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 | CARSTEN BOESS | For | For |
| | 2 | J. MARTIN CARROLL | For | For |
| | 3 | GARY M. PHILLIPS, M.D. | For | For |
| 2. | RATIFICATION OF THE APPOINTMENT OF RSM US LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

INSIGHTRA MEDICAL, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 13-Aug-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | CONSENT TO AMENDMENTS TO CERTIFICATION OF DETERMINATION, ISSUANCE OF SECURITIES AND WAIVER OF ANTI-DILUTION | Management | For | For |

INSIGHTRA MEDICAL, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 29-Oct-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | CONSENT OF ISSUANCE OF SECURITIES AND WAIVER OF FIRST OFFER | Management | For | For |

INSIGHTRA MEDICAL, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 24-Nov-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | CONSENT TO NON-WHOLLY OWNED SUBSIDIARIES | Management | For | For |

INSIGHTRA MEDICAL, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 19-Jan-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | WAIVER OF FIRST OFFER AND WAIVER OF ANTI-DILUTION | Management | For | For |

INSIGHTRA MEDICAL, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 12-Apr-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|-----------------------------------|-------------|------|------------------------|
| 1 | CONSENT AND WAIVER OF FIRST OFFER | Management | For | For |

INSMED INCORPORATED

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 457669307 | Meeting Type | Annual |
| Ticker Symbol | INSM | Meeting Date | 19-May-2016 |
| Record Date | 28-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 ALFRED F. ALTOMARI | | For | For |
| | 2 STEINAR J ENGELSEN M.D. | | For | For |
| | 3 WILLIAM H. LEWIS | | For | For |
| 2. | RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR INSMED INCORPORATED FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

INTRA-CELLULAR THERAPIES INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 46116X101 | Meeting Type | Annual |
| Ticker Symbol | ITCI | Meeting Date | 14-Jun-2016 |
| Record Date | 20-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|--------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 SHARON MATES, PH.D. | | For | For |
| | 2 RORY B. RIGGS | | For | For |
| | 3 ROBERT L. VAN NOSTRAND | | For | For |
| 2. | PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | TO APPROVE BY AN ADVISORY VOTE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT. | Management | For | For |
| 4. | TO APPROVE BY AN ADVISORY VOTE THE FREQUENCY OF HOLDING AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. | Management | 1 Year | For |

JAZZ PHARMACEUTICALS PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | G50871105 | Meeting Type | Annual |
| Ticker Symbol | JAZZ | Meeting Date | 30-Jul-2015 |
| Record Date | 01-Jun-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1A. | ELECTION OF DIRECTOR: PETER GRAY | Management | For | For |
| 1B. | ELECTION OF DIRECTOR: KENNETH W. O'KEEFE | Management | For | For |
| 1C. | ELECTION OF DIRECTOR: ELMAR SCHNEE | Management | For | For |
| 1D. | ELECTION OF DIRECTOR: CATHERINE A. SOHN | Management | For | For |
| 2. | TO APPROVE THE APPOINTMENT OF KPMG AS THE INDEPENDENT AUDITORS OF JAZZ PHARMACEUTICALS PLC FOR THE FISCAL YEAR ENDING DECEMBER 31, 2015 AND TO AUTHORIZE THE BOARD OF DIRECTORS, ACTING THROUGH THE AUDIT COMMITTEE, TO DETERMINE THE AUDITORS' REMUNERATION. | Management | For | For |
| 3. | TO AUTHORIZE JAZZ PHARMACEUTICALS PLC AND/OR ANY SUBSIDIARY OF JAZZ PHARMACEUTICALS PLC TO MAKE MARKET PURCHASES OF JAZZ PHARMACEUTICALS PLC'S ORDINARY SHARES. | Management | For | For |
| 4. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF JAZZ PHARMACEUTICALS PLC'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT. | Management | For | For |

MAGELLAN BIOSCIENCES, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 23-Mar-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1 | APPROVE SPECIFIED COMPENSATORY ARRANGEMENTS BETWEEN MAGELLAN BIOSCIENCES, INC. AND ITS NAMED EXECUTIVE OFFICERS RELATING TO THE TRANSACTION | Management | For | For |

MAGELLAN BIOSCIENCES, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 24-Mar-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1 | APPROVE THE RECEIPT OF MERGER CONSIDERATION BY VARIOUS INTERESTED ENTITIES AND INDIVIDUALS UNDER SECTION 144 OF THE DELAWARE GENERAL CORPORATION LAW | Management | For | For |
| 2 | APPROVAL OF MERGER AND RELATED TRANSACTIONS | Management | For | For |
| 3 | APPROVAL OF THE STOCKHOLDER REPRESENTATIVE | Management | For | For |
| 4 | WAIVER OF APPRAISAL RIGHTS | Management | For | For |
| 5 | ADDITIONAL AGREEMENTS AND ACKNOWLEDGEMENTS | Management | For | For |
| 6 | WAIVER OF NOTICE REQUIREMENTS | Management | For | For |
| 7 | OMNIBUS RESOLUTIONS | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

MEDIVATION, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 58501N101 | Meeting Type | Annual |
| Ticker Symbol | MDVN | Meeting Date | 22-Jun-2016 |
| Record Date | 25-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 KIM D. BLICKENSTAFF | | For | For |
| | 2 KATHRYN E. FALBERG | | For | For |
| | 3 DAVID T. HUNG, M.D. | | For | For |
| | 4 MICHAEL L. KING, PH.D. | | For | For |
| | 5 C. PATRICK MACHADO | | For | For |
| | 6 DAWN SVORONOS | | For | For |
| | 7 W. ANTHONY VERNON | | For | For |
| | 8 WENDY L. YARNO | | For | For |
| 2. | TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF PRICEWATERHOUSECOOPERS LLP AS MEDIVATION S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF MEDIVATION S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT OF MEDIVATION. | Management | For | For |
| 4. | TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE MEDIVATION, INC. AMENDED AND RESTATED 2004 EQUITY INCENTIVE AWARD PLAN TO INCREASE THE NUMBER OF SHARES OF MEDIVATION S COMMON STOCK RESERVED FOR ISSUANCE UNDER THE PLAN BY 1,600,000 SHARES AND MAKE CERTAIN OTHER CHANGES AS DESCRIBED IN PROPOSAL NO. 4 IN THE PROXY STATEMENT OF MEDIVATION. | Management | For | For |
| 5. | THE SHAREHOLDER PROPOSAL REGARDING PROXY ACCESS, IF PROPERLY PRESENTED AT THE ANNUAL MEETING. | Shareholder | Against | For |

MERRIMACK PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 590328100 | Meeting Type | Annual |
| Ticker Symbol | MACK | Meeting Date | 14-Jun-2016 |
| Record Date | 19-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--------------------|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 ROBERT J. MULROY | | For | For |
| | 2 GARY L. CROCKER | | For | For |
| | 3 JOHN M. DINEEN | | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | | |
|----|---|--|------------|-----|-----|
| | 4 | VIVIAN S. LEE, M.D. PHD | | For | For |
| | 5 | JOHN MENDELSON, M.D. | | For | For |
| | 6 | ULRIK B. NIELSEN, PH.D. | | For | For |
| | 7 | MICHAEL E. PORTER, PH.D | | For | For |
| | 8 | JAMES H. QUIGLEY | | For | For |
| | 9 | RUSSELL T. RAY | | For | For |
| 2. | | TO APPROVE, ON AN ADVISORY BASIS, OUR EXECUTIVE COMPENSATION. | Management | For | For |
| 3. | | TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

MERUS B.V.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 24-Sep-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | ADJUST THE EXERCISE PRICE OF THE OPTIONS UNDER THE OPTION PLAN 2010 AND REFUND ANY DIFFERENCES IN EXERCISE PRICE OF THE OPTIONS TO PARTICIPANTS | Management | For | For |

MERUS B.V.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 14-Oct-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | GRANT OPTIONS UNDER THE MERUS B.V. 2010 OPTION PLAN AND SET THE EXERCISE PRICE FOR EACH OPTION | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

MERUS B.V.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 22-Dec-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | APPROVE PUBLICATION OF THE ANNUAL ACCOUNTS AND THE DIRECTOR S REPORT IN THE ENGLISH LANGUAGE | Management | For | For |
| 2 | ADOPT THE 2014 ANNUAL ACCOUNTS | Management | For | For |
| 3 | APPROVE TREATMENT OF LOSS CHARGED TO RESERVES | Management | For | For |
| 4 | APPROVE DISCHARGE OF MANAGEMENT BOARD FOR FISCAL 2014 | Management | For | For |
| 5 | APPROVE DISCHARGE OF SUPERVISORY BOARD FOR FISCAL 2014 | Management | For | For |
| 6 | APPROVE ANNUAL COMPENSATION TO CERTAIN NAMED INDEPENDENT DIRECTORS | Management | For | For |
| 7 | APPROVE GRANTS OF OPTIONS TO INDEPENDENT DIRECTORS | Management | For | For |
| 8 | APPROVE RENUMERATION OF AUDIT COMMITTEE CHAIRMAN | Management | For | For |
| 9 | APPROVE RENUMERATION OF COMPENSATION COMMITTEE CHAIRMAN | Management | For | For |
| 10 | RESOLVE THAT SUCH OPTIONS AND ANNUAL COMPENSATION IN CASH WHICH HAVE NOT YET BEEN GRANTED, SHALL LAPSE WITH IMMEDIATE EFFECT UPON THE EFFECTIVENESS OF THE 2015 PLAN. | Management | For | For |

MERUS B.V.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 08-Jan-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | CONSENT TO SEND YOU THE CONVOCATION INCLUDING ALL NECESSARY INFORMATION FOR THE SHAREHOLDERS MEETINGS (GENERAL MEETING AND PREFERRED MEETING), WITHOUT TAKING INTO ACCOUNT THE CONVOCATION REQUIREMENTS, AS LONG AS THE MEETINGS ARE SCHEDULED IN 2016 | Management | For | For |
| 2 | CONSENT TO DECIDING ON SUCH MATTERS BY WRITTEN RESOLUTION OUTSIDE A MEETING, AS AN ALTERNATIVE FOR OPTION 1, IF THE COMPANY DECIDES TO DO SO FOR PRACTICAL | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

REASONS

MERUS B.V.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 02-Mar-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | RESOLUTION TO ISSUE OPTION SHARES UNDER THE MERUS B.V. 2010 EMPLOYEE OPTION PLAN | Management | For | For |
| 2 | RESOLUTION TO EXCLUDE PRE-EMPTIVE RIGHTS | Management | For | For |

MERUS B.V.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 21-Mar-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1 | GRANT INITIAL EQUITY AWARDS TO SELECT INDEPENDENT DIRECTORS AND ESTABLISH DATE OF GRANT, VESTING COMMENCEMENT DATE AND THE EXERCISE PRICE | Management | For | For |

MERUS B.V.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 03-May-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | ADOPT THE 2015 ACCOUNTS | Management | For | For |
| 2 | APPROVE TREATMENT OF LOSS CHARGED TO RESERVES | Management | For | For |
| 3 | APPROVE DISCHARGE OF MANAGEMENT BOARD FOR FISCAL 2015 | Management | For | For |
| 4 | APPROVE DISCHARGE OF SUPERVISORY BOARD FOR FISCAL 2015 | Management | For | For |

MERUS B.V.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 06-May-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1 | APPROVE THE AMENDMENT OF THE ARTICLES OF ASSOCIATION AND TO EFFECT A REVERSE STOCK SPLIT | Management | For | For |
| 2 | APPROVE THE CONVERSION OF THE COMPANY INTO A PUBLIC LIMITED LIABILITY COMPANY AND AMEND THE ARTICLES OF ASSOCIATION | Management | For | For |
| 3 | APPROVE ISSUANCE OF COMMON SHARES | Management | For | For |
| 4 | APPROVE THE CONVERSION OF ALL ISSUED PREFERRED SHARES INTO COMMON SHARES | Management | For | For |
| 5 | APPROVE RENUMERATION OF THE SUPERVISORY BOARD | Management | For | For |
| 6A | APPROVE ANY REQUIRED APPLICATION TO NASDAQ | Management | For | For |
| 6B | APPROVE OF THE COMPANY PERFORMING ALL ACTS AS THE MANAGEMENT BOARD DEEMS NECESSARY IN CONNECTION WITH OR CONDUCTIVE TO THE CONVERSION AND/OR IPO | Management | For | For |
| 6C | APPROVE THE COMPANY RATIFYING AND CONFIRMING ANY DOCUMENT, DEED OR INSTRUMENT ALREADY EXECUTED IN RELATION TO THE CONVERSION AND/OR THE IPO | Management | For | For |
| 6D | APPROVE THE TRANSFER OF THE SHARES TO SHAREHOLDERS OF CEDE & CO AFTER THE END OF THE LOCK-UP PERIOD BASED ON THE LOCK-UP AGREEMENT, IF APPLICABLE | Management | For | For |
| 7 | WAIVE ANY AND ALL PRE-EMPTIVE RIGHTS AND/OR ANTI-DILUTION PROTECTION IN RELATION TO ANY ISSUANCE OF COMMON SHARES AND/OR GRANTING RIGHTS TO SUBSCRIBE TO SHARES IN THE COMPANY S SHARE CAPITAL | Management | For | For |
| 9 | WAIVE ANY RIGHT OF FIRST REFUSAL THE PREFERRED SHAREHOLDERS MAY HAVE AND TO APPROVE SUCH TRANSFER | Management | For | For |

MERUS B.V.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 06-May-2016 |
| Record Date | N/A | | |

| Item | Proposal | Vote |
|-------------|-----------------|-------------|
|-------------|-----------------|-------------|

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | Proposed by | | For/Against Management |
|------|---|----------------|-----|---------------------------|
| 1 | APPROVE THE LISTING OF THE COMPANY S SHARES AT THE NASDAQ GLOBAL MARKET | Management | For | For |
| 2 | APPROVE A REVERSE STOCK SPLIT | Management | For | For |
| 3 | APPROVE THE CONVERSION OF THE COMPANY INTO A PUBLIC LIMITED LIABILITY COMPANY | Management | For | For |
| 4 | APPROVE THE ISSUANCE OF A NUMBER OF COMMON SHARES IN THE SHARE CAPITAL OF THE COMPANY TO THE PARTIES AND IN ACCORDANCE WITH THE NOTARIAL DEED OF ISSUE | Management | For | For |
| 5 | DELEGATE, TO THE MANAGEMENT BOARD, CERTAIN AUTHORITY TO ISSUE NEW SHARES AND GRANT RIGHTS | Management | For | For |
| 6A | APPROVE RESTRICTION AND/OR EXCLUSION OF PRE-EMPTIVE RIGHTS | Management | For | For |
| 6B | REPURCHASE SHARES IN THE CAPITAL OF THE COMPANY | Management | For | For |
| 7A | THE RIGHT TO SUBSCRIBE FOR A NUMBER OF PREFERRED SHARES IN THE COMPANY S SHARE CAPITAL TO STICHTING CONTINUITEIT MERUS AND APPROVE THE ENTERING INTO A CALL OPTION AGREEMENT | Management | For | For |
| 7B | APPROVE THAT THE MANAGEMENT BOARD SHALL PROVIDE A LOAN TO THE FOUNDATION FOR ITS PAYMENT OBLIGATIONS IN RELATION TO THE CALL OPTION | Management | For | For |
| 8 | DISMISS OR REAPPOINT CERTAIN MEMBERS OF THE SUPERVISORY BOARD | Management | For | For |
| 9 | ADOPT THE COMPANY S POLICY CONCERNING THE COMPENSATION OF THE MEMBERS OF THE MANAGEMENT BOARD | Management | For | For |
| 10 | ADOPT THE COMPANY S 2016 INCENTIVE AWARD PLAN | Management | For | For |
| 11 | APPROVE REMUNERATION OF SUPERVISORY BOARD | Management | For | For |
| 12 | APPROVE THE PROPOSAL OF THE MANAGEMENT BOARD TO DELETE CLAUSE 7.3 OF THE MERUS B.V. 2010 EMPLOYEE OPTION PLAN | Management | For | For |
| 13.A | CANCEL 1,000 COMMON SHARES IN THE CAPITAL OF THE COMPANY HELD BY STICHTING ADMINISTRATIEKANTOOR MERUS | Management | For | For |
| 13.B | CANCEL 225 COMMON SHARES IN THE CAPITAL OF THE COMPANY HELD BY STICHTING ADMINISTRATIEKANTOOR MERUS | Management | For | For |
| 14 | CONSENT TO SEND ALL INFORMATION TO THE SHAREHOLDERS BY ELECTRONIC MEANS | Management | For | For |
| 15 | DETERMINE THAT THE SHAREHOLDER S AGREEMENT SHALL TERMINATE AS PER THE EFFECTIVENESS OF THE REGISTRATION STATEMENT (WHETHER THE IPO QUALIFIES AS A QUALIFYING IPO AS DEFINED IN THE SHAREHOLDERS AGREEMENT OR NOT) | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

MYLAN N.V.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | N59465109 | Meeting Type | Special |
| Ticker Symbol | MYL | Meeting Date | 28-Aug-2015 |
| Record Date | 31-Jul-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|---------|------------------------|
| 1. | APPROVAL UNDER ARTICLE 2:107A OF THE DUTCH CIVIL CODE OF THE ACQUISITION, DIRECTLY OR INDIRECTLY (WHETHER BY WAY OF AN OFFER (AND SUBSEQUENT COMPULSORY ACQUISITION) OR ANY OTHER LEGAL ARRANGEMENT) OF ALL OR ANY PORTION OF THE ORDINARY SHARES OF PERRIGO COMPANY PLC (PERRIGO) OUTSTANDING (ON A FULLY DILUTED ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL). | Management | Against | Against |

NATERA, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 632307104 | Meeting Type | Annual |
| Ticker Symbol | NTRA | Meeting Date | 07-Jun-2016 |
| Record Date | 19-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 JAMES I. HEALY | | For | For |
| | 2 EDWARD C. DRISCOLL, JR. | | For | For |
| 2. | PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

NEUROCRINE BIOSCIENCES, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 64125C109 | Meeting Type | Annual |
| Ticker Symbol | NBIX | Meeting Date | 20-May-2016 |
| Record Date | 12-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|----------------------|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 CORINNE H. NEVINNY | | For | For |
| | 2 RICHARD F. POPS | | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|--|------------|-----|-----|
| 3 | STEPHEN SHERWIN, M.D. | | For | For |
| 2. | ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 3. | TO APPROVE AN AMENDMENT TO THE COMPANY'S CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE FROM 110,000,000 TO 220,000,000. | Management | For | For |
| 4. | TO APPROVE THE COMPANY'S 2011 EQUITY INCENTIVE PLAN, AS AMENDED. | Management | For | For |
| 5. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

NEUROVANCE, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 11-Nov-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | APPROVAL THAT THE TERMS AND CONDITIONS OF THE TERM SHEET, ARE JUST, EQUITABLE AND FAIR | Management | For | For |
| 2 | APPROVAL FOR THE COMPANY TO ENTER INTO A TERM SHEET WITH H.I.G. BIOVENTURES, LLC FOR A SERIES B PREFERRED STOCK FINANCING. | Management | For | For |

NEUROVANCE, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 09-Dec-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1 | INCREASE THE SIZE OF THE COMPANY'S BOARD TO SEVEN (7) MEMBERS | Management | For | For |
| 2 | APPROVE THE BOARD'S EXPANSION OF THE COMPANY'S BOARD OF DIRECTORS TO SEVEN (7) DIRECTORS; AND OF THE ELECTION OF MR. BAILEY TO FILL THE VACANCY CREATED BY THAT EXPANSION | Management | For | For |
| 3 | APPROVE OF THE BOARD'S HAVING AUTHORIZED AND DIRECTED THAT THE COMPANY SHOULD ENTER INTO A CONSULTING AGREEMENT; AS WELL AS AN ASSOCIATED, NONQUALIFIED STOCK OPTION FOR SHARES OF COMMON STOCK UNDER THE COMPANY'S 2011 EQUITY INCENTIVE PLAN | Management | For | For |
| 4 | AUTHORIZE, EMPOWER AND DIRECT THE CHIEF EXECUTIVE OFFICER TO TAKE ANY AND ALL ACTIONS SUCH OFFICER DEEMS NECESSARY OR APPROPRIATE TO IMPLEMENT THE FOREGOING RESOLUTIONS | Management | For | For |

NEUROVANCE, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 22-Feb-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|------------------|--------------------|-------------|-------------------------------|
| 1 | BRIDGE FINANCING | Management | For | For |

NEUROVANCE, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 29-Feb-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|-------------|-----------------|--------------------|-------------|-------------------------------|
|-------------|-----------------|--------------------|-------------|-------------------------------|

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|---|--|------------|-----|-----|
| 1 | SECOND CLOSING MAJORITY FOR BRIDGE FINANCING | Management | For | For |
|---|--|------------|-----|-----|

NEUROVANCE, INC.

| | | | |
|---------------|-----|--------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 27-Jun-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|------------------|-------------|------|------------------------|
| 1 | BRIDGE FINANCING | Management | For | For |

NEVRO CORP.

| | | | |
|---------------|-------------|--------------|-------------|
| Security | 64157F103 | Meeting Type | Annual |
| Ticker Symbol | NVRO | Meeting Date | 18-May-2016 |
| Record Date | 23-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|--------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 ALI BEHBAHANI, M.D. | | For | For |
| | 2 RAMI ELGHANDOUR | | For | For |
| | 3 WILFRED E. JAEGER, M.D. | | For | For |
| 2. | TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF THE COMPANY S BOARD OF DIRECTORS, OF PRICEWATERHOUSECOOPERS LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016 | Management | For | For |
| 3. | TO RECOMMEND, ON A NON-BINDING, ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS | Management | 1 Year | For |

NOVAVAX, INC.

| | | | |
|---------------|-------------|--------------|-------------|
| Security | 670002104 | Meeting Type | Annual |
| Ticker Symbol | NVAX | Meeting Date | 09-Jun-2016 |
| Record Date | 13-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---------------------------|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 GAIL K. BOUDREAUX | | For | For |
| | 2 MICHAEL A. MCMANUS, JR. | | For | For |
| | 3 JAMES F. YOUNG | | For | For |
| 2. | | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

TO AMEND AND RESTATE THE NOVAVAX, INC. 2015 STOCK INCENTIVE PLAN AND TO INCREASE THE NUMBER OF SHARES OF THE COMPANY S COMMON STOCK, PAR VALUE \$0.01, AVAILABLE FOR ISSUANCE THEREUNDER BY 6,000,000 SHARES.

| | | | | |
|----|---|------------|-----|-----|
| 3. | TO AMEND AND RESTATE THE NOVAVAX, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN AND TO INCREASE THE NUMBER OF SHARES OF THE COMPANY S COMMON STOCK, PAR VALUE \$0.01, AVAILABLE FOR ISSUANCE THEREUNDER BY 1,000,000 SHARES. | Management | For | For |
| 4. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

PARATEK PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 699374302 | Meeting Type | Annual |
| Ticker Symbol | PRTK | Meeting Date | 08-Jun-2016 |
| Record Date | 11-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|---------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 THOMAS J. DIETZ, PH.D. | | For | For |
| | 2 EVAN LOH, M.D. | | For | For |
| | 3 TIMOTHY R. FRANSON, M.D | | For | For |
| 2. | PROPOSAL WITHDRAWN | Management | Abstain | |
| 3. | TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

PIERIS PHARMACEUTICALS INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 720795103 | Meeting Type | Annual |
| Ticker Symbol | PIRS | Meeting Date | 28-Jun-2016 |
| Record Date | 06-May-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 CHAU KHUONG | | For | For |
| | 2 STEVEN PRELACK | | For | For |
| 2. | PROPOSAL TO APPROVE THE COMPANY S 2016 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN. | Management | For | For |
| 3. | PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

REGENERON PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 75886F107 | Meeting Type | Annual |
| Ticker Symbol | REGN | Meeting Date | 10-Jun-2016 |
| Record Date | 14-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | ELECTION OF DIRECTOR: MICHAEL S. BROWN | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|-----|--|------------|-----|-----|
| 1.2 | ELECTION OF DIRECTOR: LEONARD S. SCHLEIFER | Management | For | For |
| 1.3 | ELECTION OF DIRECTOR: GEORGE D. YANCOPOULOS | Management | For | For |
| 2. | RATIFICATION OF THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

RETROPHIN, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 761299106 | Meeting Type | Annual |
| Ticker Symbol | RTRX | Meeting Date | 18-May-2016 |
| Record Date | 23-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|----------------------|------|------------------------|
| 1 | DIRECTOR | Management | | |
| | 1 | STEPHEN ASELAGE | For | For |
| | 2 | TIM COUGHLIN | For | For |
| | 3 | CORNELIUS E. GOLDING | For | For |
| | 4 | JOHN KOZARICH | For | For |
| | 5 | GARY LYONS | For | For |
| | 6 | JEFFREY MECKLER | For | For |
| 2 | TO APPROVE THE COMPANY S 2015 EQUITY INCENTIVE PLAN, AS AMENDED, TO, AMONG OTHER ITEMS, INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER BY 1,600,000. | Management | For | For |
| 3 | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS. | Management | For | For |
| 4 | TO RATIFY THE SELECTION OF BDO USA LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

REVANCE THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 761330109 | Meeting Type | Annual |
| Ticker Symbol | RVNC | Meeting Date | 05-May-2016 |
| Record Date | 11-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 RONALD W. EASTMAN | | For | For |
| | 2 MARK A. PRYGOCKI | | For | For |
| 2. | PROPOSAL TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

SAGE THERAPEUTICS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 78667J108 | Meeting Type | Annual |
| Ticker Symbol | SAGE | Meeting Date | 22-Jun-2016 |
| Record Date | 25-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|--------|------------------------|
| 1A. | ELECTION OF DIRECTOR: KEVIN P. STARR | Management | For | For |
| 1B. | ELECTION OF DIRECTOR: JAMES FRATES | Management | For | For |
| 2. | TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | ADVISORY VOTE ON THE FREQUENCY OF ADVISORY VOTES ON EXECUTIVE COMPENSATION. | Management | 1 Year | For |

SHIRE PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 82481R106 | Meeting Type | Annual |
| Ticker Symbol | SHPG | Meeting Date | 28-Apr-2016 |
| Record Date | 18-Mar-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|------|------------------------|
| 1. | TO RECEIVE THE COMPANY S ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED DECEMBER 31, 2015. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|-----|--|------------|-----|-----|
| 2. | TO APPROVE THE DIRECTORS REMUNERATION REPORT, EXCLUDING THE DIRECTORS REMUNERATION POLICY, SET OUT ON PAGES 76 TO 101 OF THE ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED DECEMBER 31, 2015. | Management | For | For |
| 3. | TO RE-ELECT DOMINIC BLAKEMORE AS A DIRECTOR. | Management | For | For |
| 4. | TO ELECT OLIVIER BOHUON AS A DIRECTOR. | Management | For | For |
| 5. | TO RE-ELECT WILLIAM BURNS AS A DIRECTOR. | Management | For | For |
| 6. | TO RE-ELECT DR. STEVEN GILLIS AS A DIRECTOR. | Management | For | For |
| 7. | TO RE-ELECT DR. DAVID GINSBURG AS A DIRECTOR. | Management | For | For |
| 8. | TO RE-ELECT SUSAN KILSBY AS A DIRECTOR. | Management | For | For |
| 9. | TO ELECT SARA MATHEW AS A DIRECTOR. | Management | For | For |
| 10. | TO RE-ELECT ANNE MINTO AS A DIRECTOR. | Management | For | For |
| 11. | TO RE-ELECT DR. FLEMMING ORNSKOV AS A DIRECTOR. | Management | For | For |
| 12. | TO ELECT JEFFREY POULTON AS A DIRECTOR. | Management | For | For |
| 13. | TO RE-APPOINT DELOITTE LLP AS THE COMPANY S AUDITOR UNTIL THE CONCLUSION OF THE NEXT ANNUAL GENERAL MEETING OF THE COMPANY. | Management | For | For |
| 14. | TO AUTHORIZE THE AUDIT, COMPLIANCE & RISK COMMITTEE TO DETERMINE THE REMUNERATION OF THE AUDITOR. | Management | For | For |
| 15. | THAT THE AUTHORITY TO ALLOT RELEVANT SECURITIES (AS DEFINED IN THE COMPANY S ARTICLES OF ASSOCIATION (THE ARTICLES)) CONFERRED ON THE DIRECTORS BY ARTICLE 10 PARAGRAPH (B) OF THE ARTICLES BE RENEWED AND FOR THIS PURPOSE THE AUTHORISED ALLOTMENT AMOUNT SHALL BE: (A) 9,886,710.20 OF RELEVANT SECURITIES; AND (B) SOLELY IN CONNECTION WITH AN ALLOTMENT PURSUANT TO AN OFFER BY WAY OF A RIGHTS ISSUE (AS DEFINED IN THE ARTICLES, BUT ONLY IF AND TO THE EXTENT THAT SUCH OFFER IS ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL) | Management | For | For |
| 16. | THAT, SUBJECT TO THE PASSING OF RESOLUTION 15, THE AUTHORITY TO ALLOT EQUITY SECURITIES (AS DEFINED IN THE COMPANY S ARTICLES OF ASSOCIATION (THE ARTICLES)) WHOLLY FOR CASH CONFERRED ON THE DIRECTORS BY ARTICLE 10 PARAGRAPH (D) OF THE ARTICLES BE RENEWED AND FOR THIS PURPOSE THE NON PRE-EMPTIVE AMOUNT (AS DEFINED IN THE ARTICLES) SHALL BE 3,005,870.30 AND THE ALLOTMENT PERIOD SHALL BE THE PERIOD COMMENCING ON APRIL 28, 2016, AND ENDING ON THE EARLIER OF JULY 27, 2017, ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL) | Management | For | For |
| 17. | THAT THE COMPANY BE AND IS HEREBY GENERALLY AND UNCONDITIONALLY AUTHORIZED: (A) PURSUANT TO ARTICLE 57 OF THE COMPANIES (JERSEY) LAW 1991 TO MAKE MARKET PURCHASES OF ORDINARY SHARES IN THE CAPITAL OF THE COMPANY, PROVIDED THAT: (1) THE MAXIMUM NUMBER OF ORDINARY SHARES HEREBY AUTHORIZED TO BE PURCHASED IS 59,320,261; (2) THE MINIMUM | Management | For | For |

| | | | | |
|-----|---|------------|-----|-----|
| | PRICE, EXCLUSIVE OF ANY EXPENSES, WHICH MAY BE PAID FOR AN ORDINARY SHARE IS FIVE PENNCE; (3) THE MAXIMUM PRICE, EXCLUSIVE OF ANY EXPENSES, WHICH MAY BE PAID ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL) | | | |
| 18. | THAT THE AUTHORIZED SHARE CAPITAL OF THE COMPANY BE INCREASED FROM 50,000,002 TO 75,000,002, TO BE DIVIDED INTO 1,500,000,000 SHARES DESIGNATED AS ORDINARY SHARES WITH A PAR VALUE OF 5P EACH AND 2 SHARES DESIGNATED AS SUBSCRIBER ORDINARY SHARES WITH A PAR VALUE OF 1 EACH, AND THAT THE COMPANY S MEMORANDUM OF ASSOCIATION BE AMENDED ACCORDINGLY. | Management | For | For |
| 19. | THAT, WITH EFFECT FROM THE CONCLUSION OF THE ANNUAL GENERAL MEETING, THE COMPANY S ARTICLES OF ASSOCIATION BE AMENDED AND THOSE ARTICLES PRODUCED TO THE MEETING AND INITIALED BY THE CHAIRMAN BE ADOPTED AS THE COMPANY S ARTICLES OF ASSOCIATION, IN SUBSTITUTION FOR, AND TO THE EXCLUSION OF, THE EXISTING ARTICLES OF ASSOCIATION OF THE COMPANY. | Management | For | For |
| 20. | TO APPROVE THAT A GENERAL MEETING OF THE COMPANY, OTHER THAN AN ANNUAL GENERAL MEETING, MAY BE CALLED ON NOT LESS THAN 14 CLEAR DAYS NOTICE. | Management | For | For |

SHIRE PLC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 82481R106 | Meeting Type | Annual |
| Ticker Symbol | SHPG | Meeting Date | 27-May-2016 |
| Record Date | 21-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1 | APPROVAL OF THE MERGER, ALLOTMENT OF SHARES AND INCREASE IN BORROWING LIMIT THAT: (A) THE PROPOSED COMBINATION BY THE COMPANY, THROUGH ITS WHOLLY-OWNED SUBSIDIARY, BEARTRACKS, INC., WITH THE OUTSTANDING COMMON STOCK WITH BAXALTA INC. (THE MERGER), ON THE TERMS AND CONDITIONS SET OUT IN THE MERGER AGREEMENT (AS DEFINED IN, AND PARTICULARS OF WHICH ARE SUMMARISED IN, THE CIRCULAR OF THE COMPANY DATED 18 APRIL 2016), TOGETHER WITH ALL OTHER AGREEMENTS AND ANCILLARY ARRANGEMENTS ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL) | Management | For | For |
| 2 | AUTHORITY TO ALLOT SHARES THAT, SUBJECT TO AND CONDITIONAL UPON THE MERGER HAVING BEEN IMPLEMENTED AND THE NEW ORDINARY SHARES IN THE COMPANY HAVING BEEN ISSUED PURSUANT THERETO, ANY PREVIOUS AUTHORITY TO ALLOT RELEVANT SECURITIES (AS DEFINED IN THE ARTICLES), CONFERRED ON THE DIRECTORS BY SHAREHOLDERS PURSUANT TO ARTICLE 10 OF THE ARTICLES (INCLUDING ANY UNUSED AUTHORITY CONFERRED BY RESOLUTION 1 ABOVE) BE CANCELLED AND THE AUTHORITY TO ALLOT RELEVANT SECURITIES CONFERRED ON THE ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL) | Management | For | For |
| 3 | DISAPPLICATION OF PRE-EMPTION RIGHTS: THAT, SUBJECT TO THE PASSING OF RESOLUTION 2 AND SUBJECT TO AND CONDITIONAL UPON THE MERGER HAVING BEEN IMPLEMENTED AND THE NEW ORDINARY SHARES IN THE COMPANY HAVING BEEN ISSUED PURSUANT THERETO, ANY PREVIOUS AUTHORITY TO ALLOT EQUITY SECURITIES (AS DEFINED IN THE ARTICLES) WHOLLY FOR CASH CONFERRED ON THE DIRECTORS BY SHAREHOLDERS PURSUANT TO ARTICLE 10 OF THE ARTICLES OF ASSOCIATION BE CANCELLED AND THE AUTHORITY TO ALLOT EQUITY ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL) | Management | For | For |
| 4 | PURCHASE OF OWN SHARES: THAT, SUBJECT TO AND CONDITIONAL UPON THE MERGER HAVING BEEN IMPLEMENTED AND THE NEW ORDINARY | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

SHARES IN THE COMPANY HAVING BEEN ISSUED
PURSUANT THERETO, ANY PREVIOUS
AUTHORITY CONFERRED ON THE COMPANY TO
MAKE MARKET PURCHASES OF ITS SHARES AND
TO HOLD TREASURY SHARES BE CANCELLED
AND THE COMPANY BE GENERALLY AND
UNCONDITIONALLY AUTHORISED: (A) PURSUANT
TO ARTICLE 57 OF THE COMPANIES (JERSEY) LAW
1991 TO MAKE MARKET PURCHASES OF
ORDINARY SHARES IN THE ... (DUE TO SPACE
LIMITS, SEE PROXY MATERIAL FOR FULL
PROPOSAL)

TETRAPHASE PHARMACEUTICALS, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 88165N105 | Meeting Type | Annual |
| Ticker Symbol | TTPH | Meeting Date | 08-Jun-2016 |
| Record Date | 14-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 GAREN BOHLIN | | For | For |
| | 2 JOHN FREUND | | For | For |
| 2. | TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016 | Management | For | For |
| 3. | TO APPROVE, ON AN ADVISORY BASIS, OUR EXECUTIVE COMPENSATION | Management | For | For |
| 4. | TO RECOMMEND, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION | Management | 1 Year | For |

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 881624209 | Meeting Type | Annual |
| Ticker Symbol | TEVA | Meeting Date | 03-Sep-2015 |
| Record Date | 04-Aug-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1A | ELECTION OF DIRECTOR: ROGER ABRAVANEL | Management | For | For |
| 1B | ELECTION OF DIRECTOR: ROSEMARY A. CRANE | Management | For | For |
| 1C | ELECTION OF DIRECTOR: GERALD M. LIEBERMAN | Management | For | For |
| 1D | ELECTION OF DIRECTOR: GALIA MAOR | Management | For | For |
| 2 | TO APPOINT GABRIELLE GREENE-SULZBERGER TO SERVE AS A STATUTORY INDEPENDENT DIRECTOR FOR A TERM OF THREE YEARS, COMMENCING FOLLOWING THE MEETING, AND TO APPROVE HER REMUNERATION AND BENEFITS. | Management | For | For |
| 3A | TO APPROVE AN AMENDMENT TO THE COMPANY S COMPENSATION POLICY WITH RESPECT TO DIRECTOR REMUNERATION. | Management | For | For |
| 3A1 | DO YOU HAVE A PERSONAL INTEREST IN PROPOSAL 3A? NOTE: PROPOSAL 3A1, FOR=YES AGAINST=NO | Management | Against | |
| 3B | TO APPROVE THE REMUNERATION TO BE PROVIDED TO THE COMPANY S DIRECTORS. | Management | For | For |
| 3C | TO APPROVE THE REMUNERATION TO BE PROVIDED TO PROF. YITZHAK PETERBURG, CHAIRMAN OF THE BOARD OF DIRECTORS. | Management | For | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | | |
|----|--|------------|-----|-----|
| 4A | TO APPROVE AN AMENDMENT TO THE TERMS OF OFFICE AND EMPLOYMENT OF THE COMPANY'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, MR. EREZ VIGODMAN. | Management | For | For |
| 4B | TO APPROVE THE PAYMENT OF A SPECIAL BONUS TO THE COMPANY'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, MR. EREZ VIGODMAN. | Management | For | For |
| 5 | TO APPROVE THE COMPANY'S 2015 LONG-TERM EQUITY-BASED INCENTIVE PLAN. | Management | For | For |
| 6 | TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM UNTIL THE 2016 ANNUAL MEETING OF SHAREHOLDERS. | Management | For | For |

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 881624209 | Meeting Type | Special |
| Ticker Symbol | TEVA | Meeting Date | 05-Nov-2015 |
| Record Date | 06-Oct-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|-------------|---|--------------------|-------------|-------------------------------|
| 1 | APPROVAL OF THE CREATION OF A NEW CLASS OF MANDATORY CONVERTIBLE PREFERRED SHARES, NOMINAL (PAR) VALUE NIS 0.1 PER SHARE AND THE DEFINITION OF THEIR TERMS, AND CERTAIN RELATED AMENDMENTS TO TEVA S ARTICLES OF ASSOCIATION AND MEMORANDUM OF ASSOCIATION. | Management | For | For |

THE MEDICINES COMPANY

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 584688105 | Meeting Type | Annual |
| Ticker Symbol | MDCO | Meeting Date | 26-May-2016 |
| Record Date | 15-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|-------------|--|--------------------|-------------|-------------------------------|
| 1A. | ELECTION OF DIRECTOR: WILLIAM W. CROUSE | Management | For | For |
| 1B. | ELECTION OF DIRECTOR: JOHN C. KELLY | Management | For | For |
| 1C. | ELECTION OF DIRECTOR: HIROAKI SHIGETA | Management | For | For |
| 2. | APPROVE AN AMENDMENT TO THE COMPANY S CERTIFICATE OF INCORPORATION TO PROVIDE FOR THE PHASED DECLASSIFICATION OF OUR BOARD OF DIRECTORS TO BE COMPLETED UPON THE ELECTION OF DIRECTORS AT OUR 2018 ANNUAL MEETING OF STOCKHOLDERS. | Management | For | For |
| 3. | APPROVE THE 2013 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES. | Management | For | For |
| 4. | APPROVE THE 2010 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES. | Management | For | For |
| 5. | APPROVE, IN AN ADVISORY VOTE, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS PRESENTED IN THE PROXY STATEMENT. | Management | For | For |
| 6. | RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

THEROX, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 20-Apr-2016 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|---------------------------------|-------------|------|------------------------|
| 1 | APPROVAL OF REVERSE STOCK SPLIT | Management | For | For |

TROVAGENE, INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 897238309 | Meeting Type | Special |
| Ticker Symbol | TROV | Meeting Date | 23-Dec-2015 |
| Record Date | 12-Oct-2015 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | PROPOSAL TO ADOPT AN AMENDMENT TO THE TROVAGENE INC. 2014 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES RESERVED FOR ISSUANCE THEREUNDER TO 7,500,000 FROM 5,000,000. | Management | For | For |

ULTRAGENYX PHARMACEUTICAL INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 90400D108 | Meeting Type | Annual |
| Ticker Symbol | RARE | Meeting Date | 09-Jun-2016 |
| Record Date | 12-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|---|-------------|--------|------------------------|
| 1A. | ELECTION OF DIRECTOR: WILLIAM ALISKI | Management | For | For |
| 1B. | ELECTION OF DIRECTOR: LARS EKMAN, M.D., PH.D. | Management | For | For |
| 1C. | ELECTION OF DIRECTOR: MATTHEW K. FUST | Management | For | For |
| 2. | RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPANY S EXECUTIVE COMPENSATION. | Management | For | For |
| 4. | ADVISORY (NON-BINDING) VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE EXECUTIVE COMPENSATION. | Management | 1 Year | For |

VENITI, INC.

| | | | |
|----------------------|-----|---------------------|-----------------|
| Security | N/A | Meeting Type | Written Consent |
| Ticker Symbol | N/A | Meeting Date | 04-Dec-2015 |
| Record Date | N/A | | |

| Item | Proposal | Proposed by | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1 | INCREASE IN SIZE OF BOARD; AMENDMENT OF VOTING AGREEMENT | Management | For | For |
| 2 | INCREASE IN 2010 EQUITY INCENTIVE PLAN | Management | For | For |
| 3 | OMNIBUS RESOLUTIONS | Management | For | For |

VERTEX PHARMACEUTICALS INCORPORATED

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 92532F100 | Meeting Type | Annual |
| Ticker Symbol | VRTX | Meeting Date | 15-Jun-2016 |
| Record Date | 20-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|---------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 JOSHUA BOGER | | For | For |
| | 2 TERRENCE C. KEARNEY | | For | For |
| | 3 YUCHUN LEE | | For | For |
| | 4 ELAINE S. ULLIAN | | For | For |
| 2. | RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016. | Management | For | For |
| 3. | ADVISORY VOTE ON OUR NAMED EXECUTIVE OFFICER COMPENSATION. | Management | For | For |
| 4. | SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT WE TAKE NECESSARY STEPS TO DECLASSIFY OUR BOARD OF DIRECTORS. | Shareholder | Against | For |
| 5. | SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT WE ADOPT A POLICY LIMITING ACCELERATION OF EQUITY AWARDS TO SENIOR EXECUTIVES UPON A CHANGE OF CONTROL. | Shareholder | Against | For |
| 6. | SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT WE ADOPT A POLICY REQUIRING THAT SENIOR EXECUTIVES RETAIN A PERCENTAGE OF THEIR EQUITY AWARDS. | Shareholder | Against | For |
| 7. | SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING A REPORT ASSESSING THE FEASIBILITY OF INTEGRATING SUSTAINABILITY INTO PERFORMANCE MEASURES FOR SENIOR EXECUTIVE COMPENSATION. | Shareholder | Against | For |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

XENCOR INC

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 98401F105 | Meeting Type | Annual |
| Ticker Symbol | XNCR | Meeting Date | 23-Jun-2016 |
| Record Date | 26-Apr-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1. | DIRECTOR | Management | | |
| | 1 DR. BRUCE L.A. CARTER | | For | For |
| | 2 ROBERT BALTERA, JR | | For | For |
| | 3 DR. BASSIL I. DAHIYAT | | For | For |
| | 4 KURT GUSTAFSON | | For | For |
| | 5 YUJIRO S. HATA | | For | For |
| | 6 DR. A. BRUCE MONTGOMERY | | For | For |
| 2. | PROPOSAL TO RATIFY RSM US, LLP AS THE INDEPENDENT PUBLIC ACCOUNTING FIRM FOR 2016. | Management | For | For |

ZAFGEN, INC.

| | | | |
|----------------------|-------------|---------------------|-------------|
| Security | 98885E103 | Meeting Type | Annual |
| Ticker Symbol | ZFGN | Meeting Date | 30-Jun-2016 |
| Record Date | 02-May-2016 | | |

| Item | Proposal | Proposed By | Vote | For/Against Management |
|------|--|-------------|------|------------------------|
| 1.1 | ELECTION OF DIRECTOR: PETER BARRETT, PH.D. | Management | For | For |
| 1.2 | ELECTION OF DIRECTOR: FRANCES K. HELLER | Management | For | For |
| 1.3 | ELECTION OF DIRECTOR: BRUCE BOOTH, PH.D. | Management | For | For |
| 2. | TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016. | Management | For | For |

SIGNATURES

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant) Tekla Life Sciences Investors

By (Signature and Title)*

/s/ Daniel R. Omstead
(Daniel R. Omstead, President)

Date 8/29/16

*Print the name and title of each signing officer under his or her signature.